<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1701233104
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEVIKAR HCT 40/5/12.5MG FILM COATED  TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLMESARTAN MEDOXOMIL,HYDROCHLOROTHIAZIDE,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,12.5,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        110.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sevikar HCT contains three active substances: (i) Olmesartan, (ii) Amlodipine and (iii) Hydrochlorothiazide. All three substances help to control high blood pressure.</p><p>&bull; Olmesartan belongs to a group of medicines called &ldquo;angiotensin-II receptor antagonists that lower blood pressure by relaxing blood vessels.</p><p>&bull; Amlodipine belongs to a group of substances called &ldquo;calcium channel blockers. Amlodipine also lowers blood pressure by relaxing blood vessels.</p><p>&bull; Hydrochlorothiazide is one of a group of medicines called thiazide diuretics (&ldquo;water tablets&rdquo;). It lowers blood pressure by helping the body to get rid of extra fluid by making your kidneys produce more urine.</p><p>Sevikar HCT is used to treat high blood pressure in subjects who are already taking either (a) a fixed-dose combination of Olmesartan medoxomil and Amlodipine (b) a fixed-dose combination of Olmesartan medoxomil and Hydrochlorothiazide plus the Amlodipine as a single tablet or (c) a fixed-dose combination of Olmesartan medoxomil and Amlodipine plus Hydrochlorothiazide as a single tablet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Sevikar HCT if:</strong></p><p>You are allergic to Olmesartan, to Amlodipine, to Hydrochlorothiazide, to substances related to any of the 3 components or to any of the other ingredients of this medicine listed in section 6 of this leaflet. If you think you may be allergic to the components of Sevikar</p><p>HCT talk to your doctor before taking Sevikar HCT.</p><p>Sevikar HCT should not be co-administered with aliskiren in patients with diabetes mellitus or renal impairment.</p><p>You have severe kidney problems.</p><p>You have low potassium, low sodium, high calcium or high uric acid (with symptoms of gout or kidney stones) levels in your blood that have not got better when treated.</p><p>You are more than 3 months pregnant. (It is also better to avoid Sevikar HCT in early</p><p>pregnancy - see section &ldquo;Pregnancy and breast-feeding&rdquo;.)</p><p>You have severe liver problems, if bile secretion is impaired or drainage of bile from the gall bladder is blocked (e.g. by gallstones), or if you are jaundiced (yellowing of the skin and eyes).</p><p>You have very low blood pressure.</p><p>The blood flow from your heart is impaired. This may happen if the blood vessel or valve that takes blood away from your heart becomes narrow (aortic stenosis).</p><p>You have heart failure. Heart failure may make you feel short of breath or cause swelling in your feet and ankles.</p><p>Do not take Sevikar HCT if any of the above applies to you.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before using Sevikar HCT. Tell your doctor if you have any of the following health problems:</p><p>Dual Blockade of the Renin-Angiotensin-aldosterone System (RAAS):</p><p>Combination of Sevikar HCT with ACE inhibitors, or aliskiren may cause increased risks of hyperkalemia, worsening of kidney function and hypotension. Therefore, this combination should not be used, especially in patients with kidney problems.</p><p>Kidney problems or a kidney transplant.</p><p>Liver disease.</p><p>Heart failure or problems with your heart valves or heart muscle.</p><p>Severe vomiting, diarrhoea, treatment with high doses of &ldquo;water tablets&rdquo; (diuretics) or if you are on a low salt diet.</p><p>Increased potassium in your blood.</p><p>Problems with your adrenal glands</p><p>Diabetes.</p><p>Lupus erythematosus (an autoimmune disease).</p><p>Allergies or asthma.</p><p>Skin reactions such as sunburn or rash after being in the sun or using a sunbed.</p><p>As with any medicine that reduces blood pressure, an excessive drop in blood pressure may lead to a heart attack or stroke. Your doctor will therefore check your blood pressure carefully.</p><p>Sevikar HCT may cause a rise in blood cholesterol and uric acid (the cause of gout &ndash; painful swelling of the joints). Your doctor may request blood tests to check.</p><p>Sevikar HCT may also affect your body&rsquo;s salt balance. Your doctor may request blood tests to check. Possible symptoms include thirst, dryness of the mouth, muscle pain or cramps, tired muscles, low blood pressure, feeling weak, sluggish, tired, sleepy or restless, nausea, vomiting, less need to pass urine, a rapid heart rate. Tell your doctor if you notice these symptoms.</p><p>If you are due to have tests for parathyroid function you should stop taking Sevikar HCT before these tests are carried out.</p><p>You must tell your doctor if you think that you are (or might become) pregnant. Sevikar HCT is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see section &ldquo;Pregnancy and breast-feeding&rdquo;).</p><p><strong>Children and adolescents (under 18)</strong></p><p>Sevikar HCT is not recommended for children and adolescents under the age of 18.</p><p><strong>Other medicines and Sevikar HCT</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any of the following:</p><p>Dual RAAS Blockade, The combination of Sevikar HCT with Aliskiren, ACEIs or other ARBs is contraindicated in patients with diabetes mellitus or renal impairment.</p><p>Dual blockade (e.g by adding ACE inhibitor to Sevikar HCT ) should not be used, especially in patients with Kidney problems.</p><p>Lithium (a medicine used to treat mood swings and some types of depression), used at the same time as Sevikar HCT may increase the toxicity of lithium. If you have to take lithium your doctor will measure your lithium blood levels.</p><p>Diltiazem, verapamil, used for heart rhythm problems and high blood pressure.</p><p>Rifampicin, erythromycin, clarithromycin, used for tuberculosis and other infections.</p><p>St. John&rsquo;s wort (Hypericum perforatum), a herbal remedy for treatment of depression.</p><p>Cisapride, used to increase food movement in the stomach and gut.</p><p>Diphemanil, used to treat a slow heartbeat or reduce sweating.</p><p>Halofantrine, used for malaria.</p><p>Vincamine IV, used to improve circulation to the nervous system.</p><p>Amantadine, used for Parkinson&rsquo;s disease.</p><p>Potassium supplements, salt substitutes containing potassium, &ldquo;water tablets&rdquo; (diuretics), heparin (for thinning the blood and prevention of blood clots), ACE inhibitors (for blood pressure lowering), laxatives, steroids, adrenocorticotrophic hormone (ACTH), carbenoxolone (a medicine used to treat mouth and stomach ulcers), penicillin, an antibiotic), certain pain killers such as aspirin or salicylates. Using these medicines at the same time as Sevikar HCT may alter the concentration of potassium in your blood.</p><p>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs, medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis), used at the same time as Sevikar HCT may increase the risk of kidney failure. The effect of Sevikar HCT can be decreased by NSAIDs. In case of high dosages of salicylate the toxic effect on central nervous system may be increased.</p><p>Sleeping tablets, sedatives and anti-depressant medicines as using these medicines together with Sevikar HCT may cause a sudden drop in blood pressure when standing up.</p><p>Certain antacids (indigestion or heartburn remedies) as the effect of Sevikar HCT can be slightly decreased.</p><p>Other blood pressure lowering medicines as the effect of Sevikar HCT in lowering blood pressure can be increased.</p><p>Certain muscle relaxing medicines such as baclofen and tubocurarine.</p><p>Anticholinergic agents such as atropine and biperiden.</p><p>Calcium supplements.</p><p>&bull; Dantrolene (infusion for severe body temperature abnormalities).</p><p>&bull; Simvastatin, used to lower levels of cholesterol and fats (triglycerides) in the blood.</p><p>Treat certain mental health problems such as thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, amisulpride, pimozide, sultopride, tiapride, droperidol or haloperidol.</p><p>Treat low blood sugar (e. g. diazoxide) or high blood pressure (e. g. beta-blockers, methyldopa) as Sevikar HCT can affect how these drugs work.</p><p>Treat heart rhythm problems such as mizolastine, pentamidine, terfenadine, dofetilide, ibutilide or erythromycin injections.</p><p>Treat HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir)</p><p>Treat fungal infections (e. g. ketoconazole, itraconazole, amphotericin).</p><p>Treat heart problems such as quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, bepridil or digitalis.</p><p>Treat cancers such as amifostine, cyclophosphamide or methotrexate.</p><p>Increase blood pressure (such as noradrenaline) and slow heart rate</p><p>Treat infections such as the antibiotics called tetracyclines or sparfloxacin.</p><p>Treat gout such as probenecid, sulfinpyrazone and allopurinol.</p><p>Lower blood fat levels such as colestyramine and colestipol.</p><p>Stop rejection of organ transplants such as ciclosporin.</p><p>Lower blood sugar such as metformin or insulin.</p><p><strong>Taking Sevikar HCT with food and drink</strong></p><p>Sevikar HCT can be taken with or without food.</p><p>Grapefruit juice and grapefruit should not be consumed by people who are taking Sevikar HCT. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient Amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Sevikar HCT.</p><p>Take care when drinking alcohol while you are taking Sevikar HCT as some people feel faint or dizzy. If this happens to you, do not drink any alcohol.</p><p>Elderly patients</p><p>If you are over 65 years of age your doctor will regularly check your blood pressure at any dose increase, to make sure that your blood pressure does not become too low.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Pregnancy</p><p>You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking Sevikar HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Sevikar HCT. Sevikar HCT is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>If you become pregnant during therapy with Sevikar HCT please inform and see your physician without delay.</p><p>Breast-feeding</p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Sevikar HCT is not recommended for mothers, who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>You may feel sleepy, sick or dizzy or get a headache while being treated for your high blood pressure. Do not drive or use machines whilst you have symptoms. Ask your doctor for advice.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose of Sevikar HCT is one tablet per day.</p><p>The tablet can be taken with or without food. Swallow the tablet with some fluid (such as a glass of water). The tablet should not be chewed. Do not take the tablet with grapefruit juice.</p><p>If possible, take your daily dose at the same time each day, for example at breakfast time.</p><p><strong>If you take more Sevikar HCT than you should</strong></p><p>If you take more tablets than you should you may experience low blood pressure with symptoms such as dizziness, fast or slow heart beat.</p><p>If you take more tablets than you should or if a child accidentally swallows some go to your doctor or nearest emergency department immediately and take your medicine pack or this leaflet with you.</p><p>Excess fluid may accumulate in your lungs )pulmonary oedema( causing shortness of<br />breath that may develop up to 24-48 hours after intake.</p><p><strong>If you forget to take Sevikar HCT</strong></p><p>If you forget to take a dose take your normal dose the following day as usual. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Sevikar HCT</strong></p><p>It is important to continue to take Sevikar HCT unless your doctor tells you to stop.</p><p>If you have any further questions on the use of this medicine ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them</p><p>The following side effects are important and will require immediate action if you experience them.</p><p>You should stop taking Sevikar HCT and see your doctor immediately if the following symptoms</p><p>occur:</p><p>Common, affecting less than 1 in 10 people:</p><p>Angina (heart pain)</p><p>Rare, affecting less than 1 in 1000 people:</p><p>Anemia causing shortness of breath or looking pale</p><p>Blood clots</p><p>Severe, extensive, blistering skin rash</p><p>A sudden allergic reaction with shortness of breath, rash, wheezing and drop of blood pressure</p><p>Inflamed pancreas, causing abdominal pain and vomiting</p><p>Very rare, affecting less than 1 in 10,000 patients</p><p>Heart attack</p><p>Swelling of the face, tongue and windpipe which can cause great difficulty in breathing</p><p>Flaccid gut, causing vomiting and abdominal distension</p><p>Increased susceptibility to infection causing, for example, fever, sore throat or mouth ulcers</p><p>The following side-effects have also been reported:</p><p>Common, affecting less than 1 in 10 people:</p><p>Upper airways infection, bronchitis / urinary infection / gastroenteritis</p><p>Awareness of heartbeat</p><p>Dizziness, headache, tiredness, flu-like symptoms, sleepiness, confusion, weakness</p><p>Nausea, vomiting, diarrhoea, constipation, abdominal discomfort or pain</p><p>Accumulation of gas in intestines, heartburn</p><p>Swollen joints, joint pains, muscle spasms, aches and pains</p><p>Low blood pressure</p><p>Frequent need to pass urine, blood in urine</p><p>Fluid retention causing swollen limbs or face</p><p>Changes in blood test results that report on how the kidneys, liver and muscles are working</p><p>Changes in blood test results of salt balance</p><p>Raised blood sugar (may affect diabetes status)</p><p>Excess glucose in urine</p><p>Uncommon, affecting less than 1 in 100 people:</p><p>Dizziness on standing, fainting, spinning sensation (vertigo)</p><p>Reduced number of a type of blood cells known as platelets, which can result in bruising easily or a prolonged bleeding time</p><p>Anaphylactic reactions, skin rash, allergic inflammation of the skin, redness of skin, skin</p><p>discolouration or flushing, red itchy bumps (hives), sweating, itch, increased sensitivity of skin to</p><p>light causing sunburn, rash and discomfort, swelling of the face</p><p>Fast heartbeat</p><p>Difficulty sleeping sleep disturbances, mood change, irritability</p><p>Cough, dry mouth, breathlessness</p><p>Abnormally reduced appetite, weight decrease (or increase)</p><p>Tremor</p><p>Visual disturbance (including blurred vision), worsening of shortsightedness</p><p>Ringing in ears (tinnitus)</p><p>Altered sense of taste</p><p>Palpitations</p><p>Altered or decreased sensation of touch</p><p>Breast enlargement</p><p>Decreased sex drive, inability to gain erection in males</p><p>Exhaustion</p><p>Rare, affecting less than 1 in 1000 people:</p><p>Restlessness</p><p>Convulsions (fits)</p><p>Decreased tear production (important if using contact lenses)</p><p>Fever</p><p>Fluid accumulation in the lungs, pneumonia</p><p>Jaundice, inflamed gall bladder</p><p>Inflamed salivary glands</p><p>Kidney problems that may become severe, acute kidney failure</p><p>Very rare, affecting less than 1 in 10000 people:</p><p>Inflamed blood vessels</p><p>High muscle tension</p><p>Allergy</p><p style="text-indent:50px">Not known )frequency cannot be estimated from the available data(:<br />choroidal effusion )an abnor&not;mal accumulation of fluid in the suprachoroidal space(<br />-If you experience yellowing of the whites of the eyes, dark urine, itching of the<br />skin, even if you started therapy with Sevikar HCT long ago, contact your doctor<br />immediately who will evaluate your symptoms and decide on how to continue your<br />blood pressure medication,<br />&nbsp;</p><p>If you get any side effects talk to your doctor or pharmacist. This includes any side effects not</p><p>listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Do not use after the expiry date, which is stated on the carton. The expiry date refers to the last day of that month.</p><p>This medicinal product does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are Olmesartan Medoxomil, Amlodipine (as Amlodipine Besilate) and</p><p>Hydrochlorothiazide.</p><p>Each film-coated tablet contains 20 mg Olmesartan Medoxomil, 5 mg Amlodipine</p><p>(as Amlodipine Besilate) and 12.5 mg Hydrochlorothiazide.</p><p>Each film-coated tablet contains 40 mg Olmesartan Medoxomil, 5 mg Amlodipine</p><p>(as Amlodipine Besilate) and 12.5 mg Hydrochlorothiazide.</p><p>Each film-coated tablet contains 40 mg Olmesartan Medoxomil, 10 mg Amlodipine</p><p>(as Amlodipine Besilate) and 12.5 mg Hydrochlorothiazide.</p><p>Each film-coated tablet contains 40 mg Olmesartan Medoxomil, 5 mg Amlodipine</p><p>(as Amlodipine Besilate) and 25 mg Hydrochlorothiazide.</p><p>Each film-coated tablet contains 40 mg Olmesartan Medoxomil, 10 mg Amlodipine</p><p>(as Amlodipine Besilate) and 25 mg Hydrochlorothiazide.</p><p>Other ingredients are:</p><p>Tablet core: pregelatinized maize starch, silicified microcrystalline cellulose (microcrystalline</p><p>cellulose and silica colloidal anhydrous), croscarmellose sodium, magnesium stearate</p><p>Film coat: Opadry&reg; II Pink 85F24118 for Sevikar HCT 20 mg/5mg /12.5mg tablet</p><p>Opadry&reg; II Yellow 85F32331 for Sevikar HCT 40mg/5mg/12.5mg &amp; 40mg/5mg/25mg tablet</p><p>Opadry&reg; II Pink 85F25437 for Sevikar HCT 40mg/10mg/12.5mg &amp; 40mg/10mg/25mg tablet</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sevikar HCT 20 mg/5 mg/12.5 mg film-coated tablets are orange white, round film coated tablets
coded by 511 on one side, plain on the other side.
Sevikar HCT 40 mg/5 mg/12.5 mg film-coated tablets are light yellow, round film coated tablets
coded by 512 on one side, plain on the other side.
Sevikar HCT 40 mg/10 mg/12.5 mg film-coated tablets are greyish red, round film coated tablets
coded by 515 on one side, plain on the other side.
Sevikar HCT 40 mg/5 mg/25 mg film-coated tablets are light yellow, oval film coated tablets coded
by 513 on one side, plain on the other side.
Sevikar HCT 40 mg/10 mg/25 mg film-coated tablets are greyish red, oval film coated tablets
coded by 517 on one side, plain on the other side.
Sevikar HCT film-coated tablets are available:
in blister packs of 28 film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals</p><p>Saudi Arabian Japanese pharmaceutical company limited</p><p>Jeddah &ndash; Saudi Arabia</p><p>Under license from</p><p><strong>DAIICHI SANKYO CO. LTD.</strong></p><p><strong>Tokyo-Japan</strong></p><p><strong>-To report any side effect )s(</strong><br /><strong>&bull; Saudi Arabia</strong><br />- The National Pharmacovigilance Centre )NPC(:<br />- Fax: +966-11-205-7662<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa<br /><strong>&bull; Other GCC States and other Countries:</strong><br />- Please contact the relevant competent authority.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي سيفيكار اتش سي تي على ثلاثة من الأدوية الخافضة لضغط الدم المرتفع هما أولميسارتان ميدوكسوميل والأملوديبين (الأملوديبين بيسيلات) وهيدروكلوروثيازيد. حيث تساعد هذه المواد في السيطرة على ارتفاع ضغط الدم: -</p><p dir="RTL">&minus;&nbsp; أولميسارتان ميدوكسوميل ينتمي إلى مجموعة من الأدوية تسمى &quot;حاصرات مستقبل هرمون الأنجيوتنسين 2&quot; الذي يعمل على منع التأثيرات القابضة للأوعية الدموية الخاصة بهرمون الأنجيوتنسين 2 مما يؤدي إلى خفض ضغط الدم.</p><p dir="RTL">&minus;&nbsp; أملوديبين ينتمي إلى مجموعة من مواد تسمى &quot;مناهض أيون الكالسيوم أو حاصر لقنوات الكالسيوم&quot;</p><p dir="RTL">الأملوديبين يعمل على تثبيط تدفق ايونات الكالسيوم عبر الغشاء إلى داخل العضلات الملساء بالأوعية الدموية وعضلة القلب. مما يؤدي إلى استرخاء الأوعية الدموية ويقلل من ضغط الدم.</p><p dir="RTL">&minus;&nbsp; يعد هيدروكلوروثيازيد هو أحد الأدوية من مجموعة مدرات البول الثيازيدية (أقراص الماء)، وهو يخفض من ضغط الدم عن طريق مساعدة الجسم في التخلص من السوائل الزائدة من خلال جعل كليتيك تنتجان المزيد من البول.</p><p dir="RTL">يستخدم سيفيكار اتش سي تي لعلاج ارتفاع ضغط الدم في المرضى الذين يستعملون أي من الأدوية التالية</p><p dir="RTL">أ) جرعة ثابتة من أولميسارتان ميدوكسوميل والأملوديبين ب) جرعة ثابتة من أولميسارتان ميدوكسوميل وهيدروكلوروثيازيد مع الأملوديبين كجرعة منفصلة أو ج) جرعة ثابتة من أولميسارتان ميدوكسوميل والأملوديبين مع هيدروكلوروثيازيد كجرعة منفصلة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول سيفيكار اتش سي تي في الحالات التالية: </strong></p><p dir="RTL">&minus;&nbsp; إذا كنت تعاني من فرط الحساسية تجاه أولميسارتان ميدوكسوميل أو أملوديبين أو هيدروكلوروثيازيد أو تجاه المكونات الأخرى المذكورة في القسم 6 (معلومات إضافية).</p><p dir="RTL">&minus;&nbsp; إذا كنت تعتقد ان لديك حساسية تجاه اي من مكونات سيفيكار اتش سي تي تحدث الى طبيبك قبل تناول الدواء.</p><p dir="RTL">&minus;&nbsp; إذا كنت تعاني من مشاكل بالكلى.</p><p dir="RTL">&minus;&nbsp; إذا كنت تعاني من انخفاض مستويات البوتاسيوم، أو الصوديوم، أو ارتفاع مستويات الكالسيوم، أو حمض اليوريك في الدم (مع أعراض النقرس أو حصوات الكلى) التي لا تتحسن عند علاجها.</p><p dir="RTL">&minus;&nbsp; إذا كنتِ حاملاً في أكثر من ثلاثة أشهر (يفضل أيضاً عدم تناول سيفيكار اتش سي تي في الأشهر الأولى من الحمل-انظري قسم &quot;الحمل والرضاعة الطبيعية&quot;)</p><p dir="RTL">&minus;&nbsp; إذا كنتِ مرضعاً أو على وشك بدء الرضاعة الطبيعية. لا يوصى بتناول سيفيكار اتش سي تي في الأمهات المرضعات، وقد يختار لكِ طبيبك علاجاً أخر إذا كنتِ ترغبين في ممارسة الرضاعة الطبيعية.</p><p dir="RTL">يجب عدم استخدام سيفيكار اتش سي تي مع عقار اليسكارين في المرضى الذين يعانون من مرض السكري أو الفشل الكلوي.</p><p dir="RTL">&minus;&nbsp; إذا كنت تعاني من مشاكل شديدة بالكبد أو اصفرار البشرة والعينين (اليرقان) أو مشاكل مرتبطة بتصريف العصارة الصفراوية من المرارة (انسداد الجهاز الصفراوي؛ مثل حصى المرارة).</p><p dir="RTL">&minus;&nbsp; إذا كنت تعاني من انخفاض شديد بضغط الدم.</p><p dir="RTL">&minus;&nbsp; إذا كنت تعاني من نقص نتاج القلب (انخفاض كمية الدم التي يضخها القلب) قد يحدث هذا إذا كانت الأوعية الدموية أو صمام التي تأخذ الدم بعيداً عن القلب أصبح ضيقاً نتيجة (ضيق الشريان الأبهر).</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل بالقلب قد تشعر بضيق في التنفس او تورم بالقدم او الكاحل.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">أخبر /استشر طبيبك قبل تناول سيفيكار اتش سي تي في الحالات التالية:</p><p dir="RTL">نظام حاصرات الرينين انجيو تتسين الدستريون (RAAS)</p><p dir="RTL">استعمال دواء سيفيكار اتش سي تي مع مثبطات الإنزيم المحول للأنجيوتتسن، أو عقار اليسكارين قد يسبب مخاطر ارتفاع نسبة البوتاسيوم بالدم. وتدهور وظائف الكلى وانخفاض ضغط الدم ولذلك يجب الا تستعمل هذه العقاقير معاً. خصوصاً في المرضى الذين يعانون من مشاكل في الكلى.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالكلى، أو إذا كنت قد خضعت مؤخراً إلى عملية زرع كلى.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الكبد</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط القلب أو مشاكل في صمامات أو عضلة القلب</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء (الشعور بالإعياء)، أو إسهال شديد أو مستمر لعدة أيام.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول العلاج بجرعات مرتفعة من أقراص الماء (مدرات البول) أو إذا كنت تتبع نظاماً غذائياً قليل الملح</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في نسبة البوتاسيوم بالدم</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الغدد الكظرية (على سبيل المثال: الألدوستيرونية الأولية)</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكري</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذئبة حمراء (حمامية) (أحد أمراض المناعة الذاتية)</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية أو ربو</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يطلب طبيبك رؤيتك بشكل أكثر تكراراً، وإجراء بعض الاختبارات لك إذا كنت تعاني من أي من هذه الحالات\</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما هو الحال مع اي دواء خافض لضغط الدم، قد يؤدي الانخفاض المفرط في ضغط الدم لدى المرضى ممن يعانون من اضطرابات بتدفق الدم بالقلب أو بالمخ إلى نوبة قلبية، أو سكتة دماغية؛ لذا يجب أن يقوم طبيبك بفحص ضغط الدم لديك بعناية.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي سيفيكار اتش سي تي إلى ارتفاع في مستويات الدهون وحمض اليوريك في الدم _الإصابة بالنقرس-تورم مؤلم في المفاصل). قد يطلب منك طبيبك إجراء اختبار بالدم من حين إلى أخر للتحقق من ذلك.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يغير سيفيكار اتش سي تي من مستويات بعض المواد الكيميائية في الدم والتي تسمى بالإلكتروليتات (الكهارل). قد يطلب منك طبيبك إجراء اختبار بالدم من حين إلى أخر؛ للتحقق من ذلك. تكون العلامات على حدوث تغييرات في الإلكتروليتات هي: عطش، جفاف الفم، ألم أو تقلص بالعضلات، إجهاد العضلات، انخفاض ضغط الدم، شعور بالضعف، بالكسل، بالتعب، بالنعاس أو التململ، غثيان، قيء، انخفاض الحاجة إلى التبول، زيادة معدل ضربات القلب. أخبر طبيبك إذا لاحظت ظهور هذه الأعراض.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان من المقرر خضوعك لاختبارات لوظائف الغدة الدرقية، فيجب التوقف عن تناول سيفيكار اتش سي تي قبل القيام بمثل هذه الاختبارات.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت شخصاً رياضياً، فمن الممكن أن يغير هذا الدواء من نتائج اختبار الكشف عن المنشطات وجعلها إيجابية.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب إبلاغ طبيبك إذا كنت تعتقدين أنكِ حامل (أو قد تصبحين حاملاً). لا يوصى بتناول سيفيكار اتش سي تي في المراحل المبكرة من الحمل، ويجب ألا يتناول إذا تجاوز حملك الشهر الثالث، حيث قد يلحق بطفلك ضرر خطير إذا تم استخدامه في هذه المرحلة (انظري قسم &quot;الحمل&quot;)</p><p dir="RTL"><strong>الأطفال والمراهقون (أقل من 18 عام)</strong>؛ لا يوصى بتناول سيفيكار اتش سي تي في الأطفال والمراهقين الذين تقل أعمارهم عن 18 عاماً.</p><p dir="RTL"><strong>تناول أدوية أخرى مع سيفيكار اتش سي تي: - </strong></p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات الرنين انجيتتسين الأندوستيرون المزدوج.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمنع استخدام سيفيكار اتش سي تي مع عقار البسكارين أو مثبطات الإنزيم المحول للأنجيوتتسين أو غيرها من موانع مستقبلات الأنجيوتتسين في المرضى الذين يعانون من مرض السكري أو الفشل الكلوي.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استعمال حاصرات رنين انجيوتتسين المزدوج (مثالاً مع مثبطات الإنزيم المحول للأنجيوتتسين لدواء سيفيكار اتش سي تي وخاصة في المرضى الذين يعانون من مشاكل في الكلى</p><p dir="RTL">يرجى إبلاغ الطبيب، أوالصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخراً أي من الأدوية التالية:</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (دواء يستخدم لعلاج التقلبات المزاجية وبعض أنواع الاكتئاب)، قد يؤدي استخدامه في نفس وقت استخدام سيفيكار اتش سي تي إلى زيادة التسمم الناتج عن الليثيوم. إذا ينبغي عليك تناول الليثيوم، فسيقوم طبيبك بقياس مستويات الليثيوم في الدم لديك.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديلتيازيم، دواء يستخدم لعلاج المشاكل المتعلقة بنظم القلب، وارتفاع ضغط الدم.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، دواء يستخدم لعلاج الدرن (مرض السل)، وأنواع اخرى من العدوى.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (هايبريكم برفوراتم)، وهي عبارة عن علاج عشبي.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسابريد، يستخدم لزيادة حركة الطعام في المعدة والأمعاء.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديفيمانيل، يستخدم لعلاج بطء ضربات القلب أو تقليل العرق.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هالوفانترين، يستخدم لعلاج الملاريا.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمانتادين، مضا للفيروسات ولعلاج مرض الشلل الرعاش.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات غذائية تحتوي على البوتاسيوم، أو بدائل ملح تحتوي على البوتاسيوم، أو أدوية مدرة للبول، أو الهيبارين (يستخدم لزيادة سيولة الدم ومنع تكون جلطات الدم). قد يؤدي استخدام سيفيكار اتش سي تي إلى ارتفاع مستويات البوتاسيوم في الدم.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضاد الالتهاب غير الستيرويدية (NSAIDs، أدوية تستخدم لتخفيف الآلام، والتورم، وأعراض الالتهاب الأخرى، بما في ذلك التهاب المفاصل)، قد يؤدي استخدامها في نفس وقت استخدام سيفيكار اتش سي تي إلى زيادة خطر حدوث فشل كلوي. قد تقلل مضادات الالتهاب غير الستيرويدية من تأثير سيفيكار اتش سي تي.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص النوم، المهدئات والأدوية المضادة للاكتئاب؛ لأن استخدام هذه الأدوية بمصاحبة سيفيكار اتش سي تي قد يحدث هبوطاً في ضغط الدم عند النهوض.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الحموضة (علاجات عسر الهضم أو الحموضة)، حيث ينخفض تأثير سيفيكار اتش سي تي بشكل طفيف.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى خافضة لضغط الدم، حيث قد يتم زيادة تأثير سيفيكار اتش سي تي.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية مثل باكلوفين وتوبوكورارين-يستخدم لإرخاء العضلات.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الكولينيات، مثل: أتروبين وبييريدين.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكملات الغذائية التي تحتوي على الكالسيوم.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانترولين (لعلاج التغيرات الشديدة في درجة حرارة الجسم)</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيمفاستاتين، وتستخدم لخفض مستويات الكولسترول والدهون (الدهون الثلاثية) في الدم.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل: ثيوريدازين، كلوربروماين، ليفوميبروماين، تريفلوبيرازين، سياميمازين، سولبيريد، أميسولبيريد، بيموزيد، سلتوبريد، تيابريد، دروبيريدول أو هالوبيريدول، حيث يتم استخدامها لعلاج بعض الاضطرابات النفسية.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا وديازوكسيد، أدوية يتم استخدامها لعلاج ارتفاع ضغط الدم، أو انخفاض سكر الدم، على التوالي؛ لأن سيفيكار اتش سي تي يمكنه تعزيز تأثيرها على رفع سكر الدم.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل: ميزولاستين، بنتاميدين، تيرفينادين، دوفيتيليد، حقن إيبوتيليد أو إريثروميسين-قد تغير من انتظام ضربات انتظام القلب.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج فيروس نقص المناعة البشري/متلازمة نقص المناعة المكتسب &quot;الإيدز&quot; (مثل ريتونافير) أو لعلاج العدوى الفطرية (مثل كيتوكونازول وإيتراكونازول)</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمفوتيريسين، دواءً يستخدم لعلاج العدوى الفطرية.</p><p dir="RTL">بعض الأدوية مثل: كينيدين، هيدروكينيدين، ديسوبيراميد، أميودارون، سوتالول أو ديجيتاليس، حيث يتم استخدامها لعلاج مشاكل القلب.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أميفوستين وبعض الأدوية الأخرى التي تستخدم لعلاج السرطانات، مثل سيكلوفسفاميد أو ميثوتريكسات.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل: نورأدرينالين/ تستخدم لزيادة ضغط الدم ومعدل ضربات القلب البطيء.</p><p dir="RTL">بعض المضادات الحيوية التي تسمى تتراسيكلينات أو سبارفلوكساسين.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل: بروبينيسيد، سلفينبايرازون (سولفين بيرازون) وألوبيورينول، تستخدم لعلاج النقرس.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوليسترامين وكوليستيبول، أدوية خافضة لمستويات الدهون في الدم.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين/ دواء يستخدم لوقف رفض الجسم للأعضاء المزروعة.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة لمرضى السكري، مثل ميتفورمين أو إنسولين، حيث يتم استخدامها لخفض سكر الدم.</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخراً أية أدوية أخرى، بما فيها الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL"><strong>تناول سيفيكار اتش سي تي مع الطعام والشراب </strong></p><p dir="RTL">يمكن تناول سيفيكار اتش سي تي مع الطعام أو بدونه.</p><p dir="RTL">لا يجب تناول الجريب فروت أو عصير الجريب فروت مع سيفيكار اتش سي تي حيث ان ذلك قد يؤدي الى زيادة مستوى الاملوديبين في الدم والذي قد يؤدي بدوره إلى انخفاض غير متوقع في ضغط الدم بشكل كبير.</p><p dir="RTL">توخ الحذر عند تناول الكحوليات أثناء تناول سيفيكار اتش سي تي، حيث قد يشعر بعض الأشخاص بإغماء أو دوخة. إذا حدث لك ذلك، فلا تتناول أية كحوليات، بما في ذلك النبيذ أو البيرة أو المشروبات الروحية.</p><p dir="RTL"><strong>المرض من كبار السن</strong></p><p dir="RTL">في المرضى الذين تتعدى أعمارهم 65 عاماً، سيفحص الطبيب ضغط الدم بصورة منتظمة عند أية زيادة للجرعة؛ للتأكد من عدم انخفاض ضغط الدم بشكل شديد.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية:</strong></p><p dir="RTL">الحمل:</p><p dir="RTL">يجب إبلاغ طبيبك إذا كنتِ تعتقدين أنك حاملاً (أو قد تصبحين حاملا)</p><p dir="RTL">سينصحك طبيبك بالتوقف عن تناول سيفيكار اتش سي تي قبل أن تصبحي حاملا أو بمجرد معرفتك أنك حاملاً، وسينصحك بتناول دواء أخر حيث انه لا يوصى بتناول سيفيكار اتش سي تي في الأشهر الأولى من الحمل، ولا يجب تناوله إذا كنت حاملاً في أكثر من ثلاثة أشهر، حيث قد يلحق ضرراً خطيراً بطفلك إذا تم تناوله بعد الشهر الثالث من الحمل. إذا أصبحت حاملاً أثناء العلاج ب &quot; سيفيكار اتش سي تي&quot; فيرجى إخبار طبيبك وزيارته بدون تأخير.</p><p dir="RTL">الرضاعة الطبيعية</p><p dir="RTL">أخبري طبيبك إذا كنت مرضعاً أو كنتِ على وشك بدء الرضاعة الطبيعية. لا يوصى بتناول سيفيكار اتش سي تي في الأمهات المرضعات، وقد يختار لكِ طبيبك علاجاً آخر. استشيري الطبيب أو الصيدلة الخاص بكِ قبل تناول أي دواء إذا كنت حاملاً أو مرضعاً.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تشعر بنعاس أو دوخة أثناء علاج ارتفاع ضغط الدم الذي تعاني منه. إذا حدث ذلك، فلا تمارس القيادة، ولا تستخدم الآلات حتى تزول تلك الأعراض. استشر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائماً سيفيكار اتش سي تي كما أخبرك طبيبك بالضبط. إذا لم تكن متأكداً من كيفية التناول، يجب عليك مراجعة الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL">الجرعة الموصي بها من سيفيكار اتش سي تي هي حبة واحدة في اليوم الواحد.</p><p dir="RTL">يمكنك تناول سيفيكار اتش سي تي مع الطعام أو بدونه.</p><p dir="RTL">ابتلع الأقراص دائماً مع الكثير من الماء لا يؤخذ مع عصير الجريب فروت</p><p dir="RTL">لا ينبغي أن يمضغ قرص سيفيكار اتش سي تي</p><p dir="RTL">إذا كان ذلك ممكناً تناول جرعة سيفيكار اتش سي تي في نفس الوقت كل يوم، على سبيل المثال في وقت الإفطار.</p><p dir="RTL"><strong>إذا تناولت كمية من سيفيكار اتش سي تي أكثر مما يجب </strong></p><p dir="RTL">إذا تناولت كمية من سيفيكار اتش سي تي أكثر مما يجب قد يحدث لك انخفاض في ضغط الدم مع أعراض مثل الدوخة، وسرعة أو بطء ضربات القلب، أخبر الطبيب الخاص بك، أو اذهب إلى أقرب مستشف على الفور. خذ العبوة وأي أقراص متبقية من سيفيكار اتش سي تي او هذه النشرة معك حت يتسنى للأطباء معرفة ما تناولته.</p><p dir="RTL">قـد يتراكـم سـائل زائـد فـي رئتيـك (وذمة ِرئويـة) ممـا يسـبب ضيـق التنفـس الـذي قــد يظهـر فــي<br />غضــون 24-48 ســاعة بعــد الاســتهلاك<br />&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتناول سيفيكار اتش سي تي </strong></p><p dir="RTL">إذا نسيت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها، إلا إذا كان قد حان موعد الجرعة التالية. لا تتناول جرعة مضاعفة.</p><p dir="RTL"><strong>إذا توقفت عن تناول سيفيكار اتش سي تي </strong></p><p dir="RTL">استمر في تناول سيفيكار اتش سي تي، ما لم يخبرك طبيبك أن توقفه.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر الطبيب أو الصيدلي الخاص بك.<strong> </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب سيفيكار اتش سي تي أعراض جانبية، لكنها لا تحدث للجميع.</p><p dir="RTL">الأعراض الجانبية التالية مهمة وتتطلب التدخل العاجل لو شعرت بأي منهم. يجب أن تتوقف عن تناول سيفيكار اتش سي تي وتراجع طبيبك فوراً اذا حدث لك اي من الاعراض التالية:</p><p dir="RTL">شائعة، التي تؤثر على أقل من 1 في 10 شخصاً:</p><p dir="RTL">الذبحة الصدرية (ألم القلب)</p><p dir="RTL">نادرة، مما يؤثر على أقل من 1 في 1000 شخص:</p><p dir="RTL">فقر الدم يسبب ضيق في التنفس أو تبدو شاحباً</p><p dir="RTL">جلطات الدم</p><p dir="RTL">تقرحات طفح جلدي شديدة</p><p dir="RTL">رد فعل مفاجئ حساسية مع ضيق في التنفس، وطفح جلدي، وانخفاض ضغط الدم</p><p dir="RTL">التهاب البنكرياس تؤدي إلى آلام البطن والقيء</p><p dir="RTL">نادرة جداً، مما يؤثر على أقل من 1 في 000.10 مريض:</p><p dir="RTL">نوبة قلبية</p><p dir="RTL">تورم في الوجه واللسان والقصبة الهوائية والتي يمكن أن تسبب صعوبة كبيرة في التنفس</p><p dir="RTL">الوتر الرخو، مما تسبب القيء وانتفاخ البطن</p><p dir="RTL">زيادة التعرض للعدوى مما تسبب على سبيل المثال، الحمى، التهاب الحلق أو الفم قرح</p><p dir="RTL">كما تم الإبلاغ عن الآثار الجانبية التالية:</p><p dir="RTL">شائعة، التي تؤثر على أقل من 1 في 10 شخصاً:</p><p dir="RTL">عدوى الجهاز التنفسي العلوي، التهاب القصبة الهوائية/عدوى المسالك البولية/التهاب المعدة والأمعاء</p><p dir="RTL">خفقان القلب</p><p dir="RTL">الدوخة، الصداع، التعب، أعراض تشبه الانفلونزا، النعاس، الارتباك، هزال</p><p dir="RTL">الغثيان، التقيؤ، الإسهال، الإمساك، وألم في البطن</p><p dir="RTL">تراكم الغاز في الأمعاء، وحرقة</p><p dir="RTL">تورم المفاصل، آلام في المفاصل، تشنجات العضلات،</p><p dir="RTL">انخفاض ضغط الدم</p><p dir="RTL">الحاجة المتكررة إلى التبول، دم في البول</p><p dir="RTL">احتباس السوائل مما يسبب تورم الأطراف أو الوجه</p><p dir="RTL">تغير في نتائج اختبار الدم الخاص بوظائف الكلى والكبد والعضلات</p><p dir="RTL">تغير في نتائج اختبار الدم الخاص بتوازن الاملاح</p><p dir="RTL">ارتفاع نسبة السكر في الدم (قد يؤثر مرض السكري)</p><p dir="RTL">زيادة الجلوكوز في البول</p><p dir="RTL">غير شائعة، مما يؤثر على اقل من 1 في 100 شخص:</p><p dir="RTL">الدوخة على الوقوف، الاغماء، الإحساس بالدوار</p><p dir="RTL">انخفاض عدد الصفائح الدموية، والتي يمكن ان تؤدي الى كدمات بسهولة أو النزيف لفترة طويلة</p><p dir="RTL">ردود الفعل الحساسية وطفح الجلدي والتهاب حساسية في الجلد، واحمرار الجلد، تغير لون الجلد أو احمراره، التعرق، حكة، زيادة حساسية الجلد للضوء يسبب حروق الشمس، طفح جلدي، وتورم في الوجه</p><p dir="RTL">سرعة ضربات القلب</p><p dir="RTL">صعوبة في النوم واضطرابات النوم، وتغير المزاج، والتهيج</p><p dir="RTL">السعال، وجفاف الفم، وضيق التنفس</p><p dir="RTL">انخفاض غير طبيعي للشهية، انخفاض الوزن (أو زيادته)</p><p dir="RTL">رعشة</p><p dir="RTL">الاضطرابات البصرية (بما في ذلك عدم وضوح الرؤية)، وتفاقم قصر النظر</p><p dir="RTL">طنين في الأذن</p><p dir="RTL">تغير في حاسة التذوق</p><p dir="RTL">خفقان</p><p dir="RTL">تغير أو تناقص الإحساس باللمس</p><p dir="RTL">كبر حجم الثدي</p><p dir="RTL">انخفاض الرغبة الجنسية، عدم القدرة على الانتصاب عند الذكور</p><p dir="RTL">الاجهاد</p><p dir="RTL">نادرة، مما يؤثر على اقل من 1 في 1000 شخص:</p><p dir="RTL">الأرق</p><p dir="RTL">التشنجات (النوبات)</p><p dir="RTL">انخفاض إنتاج الدموع (مهم في حالة استخدام العدسات اللاصقة)</p><p dir="RTL">حمى</p><p dir="RTL">تراكم السوائل في الرئتين، والالتهاب الرئوي</p><p dir="RTL">اليرقان، التهاب المرارة</p><p dir="RTL">التهاب الغدد اللعابية</p><p dir="RTL">مشاكل في الكلي يمكن أن تصبح شديدة، الفشل الكلوي الحاد</p><p dir="RTL">نادرة جداً، مما يؤثر على أقل من 1 في 10000 الناس:</p><p dir="RTL">التهاب الأوعية الدموية</p><p dir="RTL">التوتر الشديد العضلات</p><p dir="RTL">حساسية</p><p dir="RTL">غير معروف لا يمكن تقدير معدل الحدوث من البيانات المتاحة:<br />- انخفـاض فـي الرؤيـة أو ألـم بالعيـن نتيجـة لزيـادة ضغـط العيـن ( قـد تكـون علامـات لتراكـم السـوائل<br />بيــن المشــيمية (الطبقــة التــي تحتــوي علــي الأوعيــة الدمويــة التــي تغــذي الشــبكية والصلبــة ،<br />الغطـاء الخارجـي الأبيـض للعيـن).<br />- إذا كنــت تعانــي مــن اصفــرار بيــاض العيــن ، والبــول الداكــن ، وحكــة فــي الجلــد ، حتــى لــو كنــت<br />بــدأت العــلاج بســيفيكار اتــش ســي تــي منــذ فتــرة طويلــة ، فاتصــل بطبيبــك علــى الفــور الــذي<br />ســيقيم أعراضــك ويقــرر كيفيــة متابعــة الــدم دواء الضغــط .<br />&nbsp;</p><p dir="RTL">إذا أصبح أي من الأعراض الجانبية خطيراً، أو إذا لاحظت أية أعراض جانبية غير المدرجة في هذه النشرة، فيرجى إبلاغ الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول ورؤية الأطفال</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">لا تستخدم سيفيكار اتش سي تي بعد انتهاء تاريخ الصلاحية المدون على العبوة أو الملصق.</p><p dir="RTL">لا يجب عدم التخلص من الأدوية عن طريق إلقائها في مياع الصرف أو مع المخلفات المنزلية. استفسر من الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد بحاجة لها. ستساعد هذه الإجراءات على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أملوديبين بيسيلات، أولميسارتان ميدوكسوميل وهيدروكلوروثيازيد</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل قرص يحتوي على 20 ملج أولميسارتان ميدوكسوميل، 5 ملج أملوديبين، و12.5 ملج هيدروكلوروثيازيد</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل قرص يحتوي على 40 ملج أولميسارتان ميدوكسوميل، 5 ملج أملوديبين، و12.5 ملج هيدروكلوروثيازيد</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل قرص يحتوي على 40 ملج أولميسارتان ميدوكسوميل، 10 ملج أملوديبين، و12.5 ملج هيدروكلوروثيازيد</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل قرص يحتوي على 40 ملج أولميسارتان ميدوكسوميل، 5 ملج أملوديبين، و 25 ملج هيدروكلوروثيازيد</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل قرص يحتوي على 40 ملج أولميسارتان ميدوكسوميل، 10 ملج أملوديبين، و25 ملج هيدروكلوروثيازيد</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي الذرة الاجيلاتينية، نشا، سيلسيفايد ميكروكريستالين سيلليولوز، وكروس كارميلوز الصوديوم، وستيرات الماغنسيوم.</p><p dir="RTL">أوبادري وردي 85F24118 (سيفيكار اتش سي تي 20 ملج/5 ملج/12.5 ملج)،</p><p dir="RTL">أوبادري أصفر 85F32331 (سيفيكار اتش سي تي 40 ملج/5 ملج/12.5 ملج، 40 ملج/5 ملج/ 25 ملج)،</p><p dir="RTL">أوبادري وردي 85F25437 (سيفيكار اتش سي تي 40 ملج/10 ملج/12.5 ملج، 40 ملج/10 ملج/ 25 ملج)،</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص سيفيكار اتش سي تي (20 ملج/5 ملج/12.5 ملج) هي أقراص دائرية مغلفة، لونها أبيض برتقالي، منقوش عليها 511 من أحد الوجهين تحتوي العبوة على 28 قرصاً مغلفاً</p><p>أقراص سيفيكار اتش سي تي (40 ملج/10 ملج/12.5 ملج) هي أقراص دائرية مغلفة، اصفر فاتح، منقوش عليها 512 من أحد الوجهين تحتوي العبوة على 28 قرصاً مغلفاً</p><p>أقراص سيفيكار اتش سي تي (40 ملج/10 ملج/12.5 ملج) هي أقراص دائرية مغلفة، لونها أحمر مائل الى الرمادي، منقوش عليها 515 من أحد الوجهين تحتوي العبوة على 28 قرصاً مغلفاً</p><p>أقراص سيفيكار اتش سي تي (40 ملج/5 ملج/25 ملج) هي أقراص بيضاوية مغلفة، لونها اصفر فاتح، منقوش عليها 513 من أحد الوجهين تحتوي العبوة على 28 قرصاً مغلفاً</p><p>أقراص سيفيكار اتش سي تي (40 ملج/10 ملج/25 ملج) هي أقراص بيضاوية مغلفة، لونها أحمر مائل الى الرمادي ، منقوش عليها 517 من أحد الوجهين تحتوي العبوة على 28 قرصاً مغلفاً<strong> </strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مصنع ساجا للصناعات الدوائية</p><p dir="RTL">الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة</p><p dir="RTL">جدة-المملكة العربية السعودية</p><p dir="RTL">بترخيص من</p><p dir="RTL">شركة دايشي سانكيو المحدودة</p><p dir="RTL">طوكيو-اليابان</p><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية</strong><br /><strong>&bull; المملكة العربية السعودية</strong><br />- المركز الوطني للتيقظ والسلامة الدوائية<br />+9٦٦-١١-٢0٥-٧٦٦٢ :- فاكس<br />- مركز اتصال هيئة الغذاء والدواء : ١9999<br />npc.drug@sfda.gov.sa :- البريد الإلكتروني<br />https://ade.sfda.gov.sa :- الموقع الإلكتروني<br /><strong>&bull; دول الخليج الأخرى/ الدول الأخرى</strong><br />- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sevikar HCT 20 mg/5 mg/12.5 mg film-coated tablets
Sevikar HCT 40 mg/5 mg/12.5 mg film-coated tablets
Sevikar HCT 40 mg/10 mg/12.5 mg film-coated tablets
Sevikar HCT 40 mg/5 mg/25 mg film-coated tablets
Sevikar HCT 40 mg/10 mg/25 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sevikar HCT 20 mg/5 mg/12.5 mg film-coated tablets:
Each film-coated tablet contains 20 mg olmesartan medoxomil, 5 mg amlodipine (as amlodipine
besilate) and 12.5 mg hydrochlorothiazide.
Sevikar HCT 40 mg/5 mg/12.5 mg film-coated tablets:
Each film-coated tablet contains 40 mg olmesartan medoxomil, 5 mg amlodipine (as amlodipine
besilate) and 12.5 mg hydrochlorothiazide.
Sevikar HCT 40 mg/10 mg/12.5 mg film-coated tablets:
Each film-coated tablet contains 40 mg olmesartan medoxomil, 10 mg amlodipine (as
amlodipine besilate) and 12.5 mg hydrochlorothiazide.Sevikar HCT 40 mg/5 mg/25 mg film-coated tablets:
Each film-coated tablet contains 40 mg olmesartan medoxomil, 5 mg amlodipine (as amlodipine
besilate) and 25 mg hydrochlorothiazide.
Sevikar HCT 40 mg/10 mg/25 mg film-coated tablets:
Each film-coated tablet contains 40 mg olmesartan medoxomil, 10 mg amlodipine (as
amlodipine besilate) and 25 mg hydrochlorothiazide.
Excipients:
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Sevikar HCT 20 mg/5 mg/12.5 mg film-coated tablets:
Orange white, round flm coated tablets coded by 511 on one side, plain on the other side.
Sevikar HCT 40 mg/5 mg/12.5 mg film-coated tablets:
Light yellow, round flm coated tablets coded by 512 on one side, plain on the other side.
Sevikar HCT 40 mg/10 mg/12.5 mg film-coated tablets:
Greyish red, round flm coated tablets coded by 515 on one side, plain on the other side.
Sevikar HCT 40 mg/5 mg/25 mg film-coated tablets:
Light yellow, oval flm coated tablets coded by 513 on one side, plain on the other side.
Sevikar HCT 40 mg/10 mg/25 mg film-coated tablets:
Greyish red, oval flm coated tablets coded by 517 on one side, plain on the other side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.<br />Add-on therapy<br />Sevikar HCT is indicated in adult patients whose blood pressure is not adequately controlled on<br />the combination of olmesartan medoxomil and amlodipine taken as dual-component formulation.<br />Substitution therapy<br />Sevikar HCT is indicated as substitution therapy in adult patients whose blood pressure is<br />adequately controlled on the combination of olmesartan medoxomil, amlodipine and<br />hydrochlorothiazide, taken as a dual-component (olmesartan medoxomil and amlodipine or<br />olmesartan medoxomil and hydrochlorothiazide) and a single-component formulation<br />(hydrochlorothiazide or amlodipine)<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults<br />The recommended dose of Sevikar HCT is 1 tablet per day.<br />Add-on therapy<br />Sevikar HCT 20 mg/5 mg/12.5 mg may be administered in patients whose blood pressure is not<br />adequately controlled on olmesartan medoxomil 20 mg and amlodipine 5 mg taken as dualcomponent combination.<br />Sevikar HCT 40 mg/5 mg/12.5 mg may be administered in patients whose blood pressure is not<br />adequately controlled on olmesartan medoxomil 40 mg and amlodipine 5 mg taken as dualcomponent combination or in patients whose blood pressure is not adequately controlled on<br />Sevikar HCT 20 mg/5 mg/12.5 mg.<br />Sevikar HCT 40 mg/5 mg/25 mg may be administered in patients whose blood pressure is not<br />adequately controlled on Sevikar HCT 40 mg/5 mg/12.5 mg.<br />Sevikar HCT 40 mg/10 mg/12.5 mg may be administered in patients whose blood pressure is not<br />adequately controlled on olmesartan medoxomil 40 mg and amlodipine 10 mg taken as dualcomponent combination or by Sevikar HCT 40 mg/5 mg/12.5 mg.<br />Sevikar HCT 40 mg/10 mg/25 mg may be administered in patients whose blood pressure is not<br />adequately controlled on Sevikar HCT 40 mg/10 mg/12.5 mg or by Sevikar HCT 40 mg/5 mg/25 mg.<br />A step-wise titration of the dosage of the individual components is recommended before<br />changing to the triple-component combination. When clinically appropriate, direct change from<br />dual-component combination to the triple-component combination may be considered.<br />Substitution therapy<br />Patients controlled on stable doses of olmesartan medoxomil, amlodipine and<br />hydrochlorothiazide taken at the same time as a dual-component (olmesartan medoxomil and<br />amlodipine or olmesartan medoxomil and hydrochlorothiazide) and a single-component<br />formulation (hydrochlorothiazide or amlodipine) may be switched to Sevikar HCT containing<br />the same component doses.<br />The maximum recommended dose of Sevikar HCT is 40 mg/10 mg/25 mg per day.<br />Elderly (age 65 years or over)<br />Caution, including more frequent monitoring of blood pressure, is recommended in elderly<br />patients, particularly at the maximum dose of Sevikar HCT 40 mg/10 mg/25 mg per day.<br />An increase of the dosage should take place with care in elderly patients (see sections 4.4 and<br />5.2).<br />Very limited data are available on the use of Sevikar HCT in patients aged 75 years or older.<br />Extreme caution, including more frequent monitoring of blood pressure, is recommended.<br />Renal impairment<br />The maximum dose in patients with mild to moderate renal impairment (creatinine clearance of<br />30 &ndash; 60 mL/min) is Sevikar HCT 20 mg/5 mg/12.5 mg, owing to limited experience of the 40 mg<br />olmesartan medoxomil dosage in this patient group.<br />Monitoring of serum concentrations of potassium and creatinine is advised in patients with<br />moderate renal impairment.<br />The use of Sevikar HCT in patients with severe renal impairment (creatinine clearance &lt; 30<br />mL/min) is contraindicated (see sections 4.3, 4.4 and 5.2).<br />Hepatic impairment<br />Sevikar HCT should be used with caution in patients with mild hepatic impairment (see sections<br />4.4 and 5.2).<br />In patients with moderate hepatic impairment the maximum dose should not exceed Sevikar<br />HCT 20 mg/5 mg/12.5 mg once daily. Close monitoring of blood pressure and renal function is<br />advised in patients with hepatic impairment.<br />As with all calcium antagonists, amlodipine&#39;s half-life is prolonged in patients with impaired<br />liver function and dosage recommendations have not been established. Sevikar HCT should<br />therefore be administered with caution in these patients. The pharmacokinetics of amlodipine<br />have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest<br />dose and titrated slowly in patients with impaired liver function.<br />Use of Sevikar HCT is contraindicated in patients with severe hepatic impairment (see sections<br />4.3 and 5.2), cholestasis or biliary obstruction (see section 4.3).<br />Paediatric population<br />Sevikar HCT is not recommended for use in patients aged below 18 years due to a lack of data<br />on safety and efficacy.<br />Method of administration:<br />The tablet should be swallowed with a sufficient amount of fluid (e. g. one glass of water). The<br />tablet should not be chewed and should be taken at the same time each day.<br />Sevikar HCT can be taken with or without food<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to dihydropyridine derivates or to sulfonamide-derived
substances (since hydrochlorothiazide is a sulfonamide-derived drug) or to any of the excipients
listed in section 6.1.
Severe renal impairment (see sections 4.4 and 5.2).
Refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia.
Severe hepatic insufficiency, cholestasis and biliary obstructive disorders (see section 5.2).
2nd and 3rd trimester of pregnancy (see sections 4.4 and 4.6).
Sevikar HCT should not be co-administered with aliskiren in patients with diabetes mellitus or
renal impairment
Due to the amlodipine component, Sevikar HCT is contraindicated in patients with:
- Shock (including cardiogenic shock).
- Severe hypotension
- Obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis).
- Haemodynamically unstable heart failure after acute myocardial infarction
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients with hypovolaemia or sodium depletion:<br />Symptomatic hypotension may occur in patients who are volume and/or sodium depleted as a<br />result of vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting, especially after<br />the first dose. Correction of this condition prior to administration of Sevikar HCT or close<br />medical supervision at the start of the treatment is recommended.<br />Other conditions with stimulation of the renin-angiotensin-aldosterone system:<br />In patients whose vascular tone and renal function depend predominantly on the activity of the<br />renin-angiotensin-aldosterone system (e. g. patients with severe congestive heart failure or<br />underlying renal disease, including renal artery stenosis), treatment with medicinal products that<br />affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely,<br />acute renal failure.<br />Dual Blockade of the Renin-Angiotensin-aldosterone System (RAAS):<br />Combination of Sevikar HCT with ACE inhibitors, or aliskiren may cause increased risks of<br />hyperkalemia, worsening of kidney function and hypotension. Therefore, this combination<br />should not be used, especially in patients with kidney problems.<br />Renovascular hypertension:<br />There is an increased risk of severe hypotension and renal insufficiency when patients with<br />bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated<br />with medicinal products that affect the renin-angiotensin-aldosterone system.<br />Renal impairment and kidney transplantation:<br />When Sevikar HCT is used in patients with impaired renal function, periodic monitoring of<br />serum concentrations of potassium and creatinine is recommended.<br />Use of Sevikar HCT is not recommended in patients with severe renal impairment (creatinine<br />clearance &lt; 30 mL/min) (see sections 4.2, 4.3 and 5.2).<br />Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function.<br />If progressive renal impairment becomes evident, careful reappraisal of therapy is necessary,<br />with consideration given to discontinuing diuretic therapy.<br />There is no experience of the administration of Sevikar HCT in patients with a recent kidney<br />transplant or in patients with end-stage renal impairment (i. e. creatinine clearance &lt; 12<br />mL/min).<br />Hepatic impairment:<br />Exposure to amlodipine and olmesartan medoxomil is increased in patients with hepatic<br />impairment (see section 5.2).<br />Furthermore, minor alterations of fluid and electrolyte balance during thiazide therapy may<br />precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease.<br />Care should be taken when Sevikar HCT is administered in patients with mild to moderate<br />hepatic impairment.<br />In patients with moderate hepatic impairment, the dose of olmesartan medoxomil should not<br />exceed 20 mg (see section 4.2).<br />In patients with impaired hepatic function, amlodipine should be initiated at the lower end of the<br />dosing range and caution should be used, both on initial treatment and when increasing the dose.<br />Use of Sevikar HCT is contraindicated in patients with severe hepatic impairment, cholestasis or<br />biliary obstruction (see section 4.3).<br />Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:<br />Due to the amlodipine component of Sevikar HCT, as with other vasodilators, special caution is<br />indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic<br />cardiomyopathy.<br />Primary aldosteronism:<br />Patients with primary aldosteronism generally will not respond to anti-hypertensive medicinal<br />products acting through inhibition of the renin-angiotensin system. Therefore, the use of Sevikar<br />HCT is not recommended in such patients.<br />Metabolic and endocrine effects:<br />Thiazide therapy may impair glucose tolerance. In diabetic patients dosage adjustments of<br />insulin or oral hypoglycaemic agents may be required (see section 4.5). Latent diabetes mellitus<br />may become manifest during thiazide therapy.<br />Increases in cholesterol and triglyceride levels are undesirable effects known to be associated<br />with thiazide diuretic therapy.<br />Hyperuricaemia may occur or frank gout may be precipitated in some patients receiving thiazide<br />therapy.<br />Electrolyte imbalance:<br />As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should<br />be performed at appropriate intervals.<br />Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (including<br />hypokalaemia, hyponatraemia and hypochloraemic alkalosis). Warning signs of fluid or<br />electrolyte imbalance are dryness of the mouth, thirst, weakness, lethargy, drowsiness,<br />restlessness, muscle pain or cramps, muscle fatigue, hypotension, oliguria, tachycardia, and<br />gastrointestinal disturbances such as nausea or vomiting (see section 4.8).<br />The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients<br />experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes<br />and in patients receiving concomitant therapy with corticosteroids or ACTH (see section 4.5).<br />Conversely, due to antagonism at the angiotensin-II receptors (AT1) through the olmesartan<br />medoxomil component of Sevikar HCT hyperkalaemia may occur, especially in the presence of<br />renal impairment and/or heart failure, and diabetes mellitus. Close monitoring of serum<br />potassium in patients at risk is recommended. Potassium-sparing diuretics, potassium<br />supplements or potassium-containing salt substitutes and other medicinal products that may<br />increase serum potassium levels (e. g. heparin) should be co-administered cautiously with<br />Sevikar HCT (see section 4.5) and with frequent monitoring of potassiuim levels.<br />There is no evidence that olmesartan medoxomil would reduce or prevent diuretic-induced<br />hyponatraemia. Chloride deficit is generally mild and usually does not require treatment.<br />Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation<br />of serum calcium in the absence of known disorders of calcium metabolism.<br />Hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be<br />discontinued before carrying out tests for parathyroid function.<br />Thiazides have been shown to increase the urinary excretion of magnesium, which may result in<br />hypomagnesaemia.<br />Dilutional hyponatraemia may occur in oedematous patients in hot weather.<br />Lithium:<br />As with other angiotensin II receptor antagonists, the coadministration of Sevikar HCT and<br />lithium is not recommended (see section 4.5).<br />Heart failure:<br />As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal<br />function may be anticipated in susceptible individuals.<br />In patients with severe heart failure whose renal function may depend on the activity of the<br />renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme (ACE)<br />inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or<br />progressive azotaemia and (rarely) with acute renal failure and/or death.<br />Patients with heart failure should be treated with caution. In a long-term, placebo controlled<br />study of amlodipine in patients with severe heart failure (NYHA III and IV), the reported<br />incidence of pulmonary oedema was higher in the amlodipine group than in the placebo group<br />(see section 5.1). Calcium channel blockers, including amlodipine, should be used with caution<br />in patients with congestive heart failure, as they may increase the risk of future cardiovascular<br />events and mortality.<br />Pregnancy:<br />Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued<br />angiotensin II receptor antagonists therapy is considered essential, patients planning pregnancy<br />should be changed to alternative anti-hypertensive treatments which have an established safety<br />profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II<br />receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy<br />should be started (see sections 4.3 and 4.6).<br />Paediatric population:<br />Sevikar HCT is not indicated in children and adolescents under the age of 18 years.<br />Elderly patients:<br />In the elderly, increase of the dosage should take place with care (see section 5.2).<br />Photosensitivity:<br />Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If<br />photosensitivity reaction occurs during treatment with Sevikar HCT, it is recommended to stop<br />the treatment. If re-administration of the diuretic is deemed necessary, it is recommended to<br />protect the areas exposed to the sun or to artificial UVA.<br />Other:<br />As with any antihypertensive agent, excessive blood pressure reduction in patients with<br />ischaemic heart disease or ischaemic cerebrovascular disease could result in a myocardial<br />infarction or stroke.<br />Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history<br />of allergy or bronchial asthma, but are more likely in patients with such a history.<br />Exacerbation or activation of systemic lupus erythematosus has been reported with the use of<br />thiazide diuretics.<br />As with all other angiotensin II receptor antagonists, the blood pressure lowering effect of<br />olmesartan is somewhat less in black patients than in non-black patients, however, this effect was<br />not seen in one of the three clinical trials with Sevikar HCT that included black patients (30 %),<br />see also section 5.1<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Potential interactions related to the Sevikar HCT combination:<br />Concomitant use not recommended<br />Dual RAAS Blockade:<br />The combination of Sevikar HCT with Aliskiren, ACEIs or other ARBs is contraindicated in<br />patients with diabetes mellitus or renal impairment.<br />Dual blockade (e.g by adding ACE inhibitor to Sevikar ) should not be used, especially in<br />patients with Kidney problems.<br />Lithium:<br />Reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with angiotensin converting enzyme inhibitors and, rarely,<br />with angiotensin II receptor antagonists. In addition, renal clearance of lithium is reduced by<br />thiazides and consequently the risk of lithium toxicity may be increased. Therefore use of<br />Sevikar HCT and lithium in combination is not recommended (see section 4.4). If use of the<br />combination proves necessary, careful monitoring of serum lithium levels is recommended.<br />Concomitant use requiring caution<br />Baclofen:<br />Potentiation of antihypertensive effect may occur.<br />Non-steroidal anti-inflammatory medicinal products:<br />NSAIDs (i.e. acetylsalicylic acid (&gt; 3 g/day), COX-2 inhibitors and non-selective NSAIDs) may<br />reduce the antihypertensive effect of thiazide diuretics and angiotensin II receptor antagonists.<br />In some patients with compromised renal function (e. g. dehydrated patients or elderly patients<br />with compromised renal function) the co-administration of angiotensin II receptor antagonists<br />and agents that inhibit cyclooxygenase may result in further deterioration of renal function,<br />including possible acute renal failure, which is usually reversible. Therefore, the combination<br />should be administered with caution, especially in the elderly. Patients should be adequately<br />hydrated and consideration should be given to monitoring of renal function after initiation of<br />concomitant therapy and periodically thereafter.<br />Concomitant use to be taken into account<br />Amifostine:<br />Potentiation of antihypertensive effect may occur.<br />Other antihypertensive agents:<br />The blood pressure lowering effect of Sevikar HCT can be increased by concomitant use of other<br />antihypertensive medicinal products.<br />Alcohol, barbiturates, narcotics or antidepressants:<br />Potentiation of orthostatic hypotension may occur.<br />Potential interactions related to olmesartan medoxomil:<br />Concomitant use not recommended<br />Medicinal products affecting potassium levels:<br />Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes<br />containing potassium or other medicinal products that may increase serum potassium levels (e. g.<br />heparin, ACE inhibitors) may lead to increases in serum potassium (see section 4.4). If medicinal<br />products that affect potassium are to be prescribed in combination with Sevikar HCT, monitoring<br />of serum potassium is advised.<br />Additional information<br />After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in<br />bioavailability of olmesartan was observed.<br />Olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics<br />of warfarin or the pharmacokinetics of digoxin.<br />Coadministration of olmesartan medoxomil with pravastatin had no clinically relevant effects on<br />the pharmacokinetics of either component in healthy subjects.<br />Olmesartan had no clinically relevant inhibitory effects on human cytochrome P450 enzymes<br />1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4 in vitro, and had no or minimal inducing effects on<br />rat cytochrome P450 activities. No clinically relevant interactions between olmesartan and<br />medicinal products metabolised by the above cytochrome P450 enzymes are expected.<br />Potential interactions related to amlodipine<br />Concomitant use requiring caution<br />Effects of other medicinal products on amlodipine<br />CYP3A4 inhibitors:<br />Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors,<br />azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may<br />give rise to significant increase in amlodipine exposure. The clinical translation of these<br />pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose<br />adjustment may thus be required.<br />CYP3A4 inducers:<br />There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The<br />concomitant use of CYP3A4 inducers (i. e. rifampicin, hypericum perforatum) may give a lower<br />plasma concentration of amlodipine. Amlodipine should be used with caution together with<br />CYP3A4 inducers.<br />Administration of amlodipine with grapefruit or grapefruit juice is not recommended as<br />bioavailability may be increased in some patients resulting in increased blood pressure lowering<br />effects.<br />Dantrolene (infusion): In animals, lethal ventricular fibrillation and cardiovascular collapse are<br />observed in association with hyperkalemia after administration of verapamil and intravenous<br />dantrolene. Due to risk of hyperkalemia, it is recommended that the co-administration of calcium<br />channel blockers such as amlodipine be avoided in patients susceptible to malignant<br />hyperthermia and in the management of malignant hyperthermia.<br />Effects of amlodipine on other medicinal products<br />The blood pressure-lowering effect of amlodipine adds to the blood pressure-lowering effects of<br />other antihypertensive agents.<br />In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin,<br />digoxin, warfarin or ciclosporin.<br />Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin<br />resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the<br />dose of simvastatin in patients on amlodipine to 20 mg daily<br />Potential interactions related to hydrochlorothiazide:<br />Concomitant use not recommended<br />Medicinal products affecting potassium levels:<br />The potassium-depleting effect of hydrochlorothiazide (see section 4.4) may be potentiated by<br />the coadministration of other medicinal products associated with potassium loss and<br />hypokalaemia (e. g. other kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin,<br />carbenoxolone, penicillin G sodium or salicylic acid derivatives). Such concomitant use is<br />therefore not recommended.<br />Concomitant use requiring caution<br />Calcium salts:<br />Thiazide diuretics may increase serum calcium owing to decreased excretion. If calcium<br />supplements must be prescribed, serum calcium should be monitored and calcium dosage<br />adjusted accordingly.<br />Cholestyramine and colestipol resins:<br />Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.<br />Digitalis glycosides:<br />Thiazide-induced hypokalaemia or hypomagnesaemia may favour the onset of digitalis-induced<br />cardiac arrhythmias.<br />Medicinal products affected by serum potassium disturbances:<br />Periodic monitoring of serum potassium and ECG is recommended when Sevikar HCT is<br />administered with medicinal products affected by serum potassium disturbances (e. g. digitalis<br />glycosides and antiarrhythmics) and with the following torsades de pointes (ventricular<br />tachycardia)-inducing medicinal products (including some antiarrhythmics), hypokalaemia being<br />a predisposing factor to torsades de pointes (ventricular tachycardia):<br />- Class Ia antiarrhythmics (e. g. quinidine, hydroquinidine, disopyramide).<br />- Class III antiarrhythmics (e. g. amiodarone, sotalol, dofetilide, ibutilide).<br />- Some antipsychotics (e. g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine,<br />cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol).<br />- Others (e. g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin,<br />pentamidine, sparfloxacin, terfenadine, vincamine IV).<br />Non-depolarizing skeletal muscle relaxants (e. g. tubocurarine):<br />The effect of nondepolarizing skeletal muscle relaxants may be potentiated by<br />hydrochlorothiazide.<br />Anticholinergic agents (e. g. atropine, biperiden):<br />Increase of the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility<br />and stomach emptying rate.<br />Antidiabetic medicinal products (oral agents and insulin):<br />The treatment with a thiazide may influence the glucose tolerance. Dosage adjustment of the<br />antidiabetic medicinal product may be required (see section 4.4).<br />Metformin:<br />Metformin should be used with caution because of the risk of lactic acidosis induced by possible<br />functional renal failure linked to hydrochlorothiazide.<br />Beta-blockers and diazoxide:<br />The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.<br />Pressor amines (e. g. noradrenaline):<br />The effect of pressor amines may be decreased.<br />Medicinal products used in the treatment of gout (e. g. probenecid, sulfinpyrazone and<br />allopurinol):<br />Dosage adjustment of uricosuric medicinal products may be necessary since hydrochlorothiazide<br />may raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may<br />be necessary. Coadministration of a thiazide may increase the incidence of hypersensitivity<br />reactions to allopurinol.<br />Amantadine:<br />Thiazides may increase the risk of adverse effects caused by amantadine.<br />Cytotoxic agents (e. g. cyclophosphamide, methotrexate):<br />Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their<br />myelosuppressive effects.<br />Salicylates:<br />In case of high dosages of salicylates hydrochlorothiazide may enhance the toxic effect of the<br />salicylates on the central nervous system.<br />Methyldopa:<br />There have been isolated reports of haemolytic anaemia occurring with concomitant use of<br />hydrochlorothiazide and methyldopa.<br />Ciclosporin:<br />Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type<br />complications.<br />Tetracyclines:<br />Concomitant administration of tetracyclines and thiazides increases the risk of tetracyclineinduced increase in urea. This interaction is probably not applicable to doxycycline<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The use of Sevikar HCT is contra-indicated during the 2nd and 3rd trimester of pregnancy (see<br />sections 4.3 and 4.4). Given the effects of the individual components in this combination product<br />on pregnancy, the use of Sevikar HCT is not recommended during the first trimester of<br />pregnancy (see section 4.4).<br />Olmesartan medoxomil<br />The use of angiotensin II receptor antagonists is not recommended during the first trimester of<br />pregnancy (see section 4.4). The use of angiotensin II receptor antagonists is contra-indicated<br />during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE<br />inhibitors during the first trimester of pregnancy has not been conclusive; however a small<br />increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk<br />with angiotensin II receptor antagonists, similar risks may exist for this class of drugs. Unless<br />continued angiotensin receptor blocker therapy is considered essential, patients planning<br />pregnancy should be changed to alternative anti-hypertensive treatments, which have an<br />established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with<br />angiotensin II receptor antagonists should be stopped immediately, and, if appropriate,<br />alternative therapy should be started.<br />Exposure to angiotensin II receptor antagonists therapy during the 2nd and 3rd trimesters is<br />known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull<br />ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see<br />also section 5.3).<br />Should exposure to angiotensin II receptor antagonists have occurred from the 2nd trimester of<br />pregnancy, ultrasound check of renal function and skull is recommended.<br />Infants, whose mothers have taken angiotensin II receptor antagonists should be closely observed<br />for hypotension (see also sections 4.3 and 4.4).<br />Hydrochlorothiazide<br />There is limited experience with hydrochlorothiazide during pregnancy, especially during the<br />first trimester. Animal studies are insufficient.<br />Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of<br />hydrochlorothiazide its use during the 2nd and 3rd trimester may compromise foeto-placental<br />perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte<br />balance and thrombocytopenia.<br />Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a<br />beneficial effect on the course of the disease.<br />Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in<br />rare situations where no other treatment could be used.<br />Amlodipine<br />Data on a limited number of exposed pregnancies do not indicate that amlodipine or other<br />calcium receptor antagonists have a harmful effect on the health of the fetus. However, there<br />may be a risk of prolonged delivery.<br />Lactation<br />Because no information is available regarding the use of Sevikar HCT during breastfeeding,<br />Sevikar HCT is not recommended and alternative treatments with better established safety<br />profiles during breast-feeding are preferable, especially while nursing a newborn or preterm<br />infant.<br />Olmesartan is excreted into the milk of lactating rats. However, it is not known whether<br />olmesartan passes into human milk. It is not known whether amlodipine is excreted in breast<br />milk. Similar calcium channel blockers of the dihydropyridine type are excreted in breast milk.<br />Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses<br />causing intense diuresis can inhibit the milk production. The use of Sevikar HCT during breast<br />feeding is not recommended. If Sevikar HCT is used during breast feeding, doses should be kept<br />as low as possible.<br />Fertility<br />Reversible biochemical changes in the head of spermatozoa have been reported in some patients<br />treated by calcium channel blockers.<br />Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat<br />study, adverse effects were found on male fertility (see section 5.3<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.<br />However, it should be borne in mind that dizziness, headache, nausea or fatigue may<br />occasionally occur in patients taking antihypertensive therapy and that these symptoms may<br />impair the ability to react. Caution is recommended especially at the start of treatment<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile:<br />The safety of Sevikar HCT was investigated in clinical trials in 7826 patients receiving<br />olmesartan medoxomil in combination with amlodipine and hydrochlorothiazide.<br />Adverse reactions from clinical trials, post-authorization safety studies and spontaneous<br />reporting are summarized in table 1 for Sevikar HCT as well as for the individual components<br />olmesartan medoxomil, amlodipine and hydrochlorothiazide based on the known safety profile<br />of the single components.<br />The most commonly reported adverse reactions during treatment with Sevikar HCT are<br />peripheral oedema, headache and dizziness.<br />b. Tabulated list of Adverse reaction:<br />The following terminologies have been used in order to classify the occurrence of undesirable<br />effects:<br />Very common (&ge;1/10)<br />Common (&ge;1/100 to &lt;1/10)<br />Uncommon (&ge;1/1,000 to &lt;1/100)<br />Rare (&ge;1/10,000 to &lt;1/1,000)<br />Very rare (&lt;1/10,000)<br />&nbsp;</p><p>Table 1: Overview of adverse reactions with Sevikar HCT and the single components</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>SEVIKAR HCT</strong></p></td><td style="vertical-align:top"><p><strong>Olmesarta n</strong></p></td><td style="vertical-align:top"><p><strong>Amlodipin</strong></p></td><td style="vertical-align:top"><p><strong>HCTZ</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sialadenitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Leucopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Bone marrow depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia/Agranulocytosi s</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Aplastic anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Drug hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="14" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Glycosuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatriaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercolesterinaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemic alkalosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hyperamylasaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Psychiatri c disorders</p></td><td style="vertical-align:top"><p>Confusional state</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Apathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Irritability</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Restlessness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Mood changes (including anxiety)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disorders (including insomnia)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Postural dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Presyncope</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="10" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypertonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypoaesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral neuropathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Convulsions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Loss of appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Visual disturbance (including diplopia, blurred vision)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Lacrimation decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Worsening of myopia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>choroidal effusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Xanthopsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon (incl. aggravatio n of angina pectoris)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="6" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vasculitis (including necrotising angiitis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Embolism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Acute interstitial pneumonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory distress</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="12" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Altered bowel habits (including diarrhoea and constipation)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Meteorism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastric irritation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gingival hyperplasia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paralytic ileus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Jaundice (intrahepatic cholestatic icterus)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Acute cholecystitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Autoimmune hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="19" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Allergic dermatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erythema multiforme</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cutaneous lupus erythematodes-like reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Exanthema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Exfoliative dermatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hyperhydrosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Photosensitivity reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Quincke oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reactivation of cutaneous lupus erythematodes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Skin discoloration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Uncommo</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Musculoskeleta l and connective tissue disorders</p></td><td style="vertical-align:top"><p>Muscle spasm</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Joint swelling</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Ankle swelling</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arthritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Paresis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Pollakiuria</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Increased urinary frequency</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Micturition disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nocturia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral oedema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Influenza-like symptoms</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood uric acid increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood potassium decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gamma glytamyl transferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic enzymes increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very rare (mostly consistent with cholestatis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatine phosphokinase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Weight decrease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Weight increase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>c. Description of selected adverse reaction:<br />Single cases of rhabdomyolysis have been reported in temporal association with the intake of<br />angiotensin II receptor blockers. Single cases of extrapyramidal syndrome have been reported in<br />patients treated with amlodipine</p><p>Cases of autoimmune hepatitis with a latency of few months to years have been reported post-marketing, that were reversible after the withdrawal of olmesartan.</p><p>Further adverse reactions reported in clinical trials or from post marketing experience with a<br />fixed-dose combination of olmesartan medoxomil and amlodipine and not already reported for<br />Sevikar HCT, olmesartan medoxomil monotherapy or amlodipine monotherapy or reported in a<br />higher frequency for the dual combination (Table 2)<br /><img alt="" width="535" height="37" src="data:image/png;base64,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" /></p><p><img alt="" width="521" height="407" src="data:image/png;base64,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" /></p><p>Post Marketing Experience:<br />Data from one controlled trial and an epidemiologic study have suggested that high-dose<br />olmesartan may increase cardiovascular (CV) risk in diabetic patients, but the overall data are<br />not conclusive. The randomized, placebo-controlled, double-blind ROADMAP trial<br />(Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention trial, n=4447) examined<br />the use of olmesartan, 40 mg daily, vs. placebo in patients with type 2 diabetes mellitus,<br />normoalbuminuria, and at least one additional risk factor for CV disease. The trial met its<br />primary endpoint, decrease in time-to-onset of microalbuminuria, but olmesartan had no<br />beneficial effect on decline in glomerular filtration rate (GFR). There was a finding of increased<br />CV mortality (adjudicated sudden cardiac death, fatal myocardial infarction, fatal stroke,<br />revascularization death) in the olmesartan group compared to the placebo group (15 olmesartan<br />vs. 3 placebo, HR 4.9, 95% confidence interval [CI], 1.4, 17), but the risk of non-fatal<br />myocardial infarction was lower with olmesartan (HR 0.64, 95% CI 0.35, 1.18).<br />The epidemiologic study included patients 65 years and older with overall exposure of &gt;300,000<br />patient-years. In the sub-group of diabetic patients receiving high-dose olmesartan (40 mg/d) for<br />&gt; 6 months, there appeared to be an increased risk of death (HR 2.0, 95% CI 1.1, 3.8) compared<br />to similar patients taking other angiotensin receptor blockers. In contrast, high-dose olmesartan<br />use in non-diabetic patients appeared to be associated with a decreased risk of death (HR 0.46,<br />95% CI 0.24, 0.86) compared to similar patients taking other angiotensin receptor blockers. No<br />differences were observed between the groups receiving lower doses of olmesartan compared to<br />other angiotensin blockers or those receiving therapy for &lt; 6 months.<br />Overall, these data raise a concern of a possible increased CV risk associated with the use of<br />high-dose olmesartan in diabetic patients. There are, however, concerns with the credibility of<br />the finding of increased CV risk, notably the observation in the large epidemiologic study for a<br />survival benefit in non-diabetics of a magnitude similar to the adverse finding in diabetics.<br />d. Other special population:<br />Renal impairment and kidney transplantation:<br />When Sevikar HCT is used in patients with impaired renal function, periodic monitoring of<br />serum concentrations of potassium and creatinine is recommended.<br />Use of Sevikar HCT is not recommended in patients with severe renal impairment (creatinine<br />clearance &lt; 30 mL/min) (see sections 4.2, 4.3 and 5.2).<br />Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function.<br />If progressive renal impairment becomes evident, careful reappraisal of therapy is necessary,<br />with consideration given to discontinuing diuretic therapy.<br />There is no experience of the administration of Sevikar HCT in patients with a recent kidney<br />transplant or in patients with end-stage renal impairment (i. e. creatinine clearance &lt; 12<br />mL/min).<br />Hepatic impairment:<br />Exposure to amlodipine and olmesartan medoxomil is increased in patients with hepatic<br />impairment (see section 5.2).<br />Furthermore, minor alterations of fluid and electrolyte balance during thiazide therapy may<br />precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease.<br />Care should be taken when Sevikar HCT is administered in patients with mild to moderate<br />hepatic impairment.<br />In patients with moderate hepatic impairment, the dose of olmesartan medoxomil should not<br />exceed 20 mg (see section 4.2).<br />In patients with impaired hepatic function, amlodipine should be initiated at the lower end of the<br />dosing range and caution should be used, both on initial treatment and when increasing the dose.<br />Use of Sevikar HCT is contraindicated in patients with severe hepatic impairment, cholestasis or<br />biliary obstruction (see section 4.3)<br />&nbsp;</p><p><strong>To report any side effect (s)</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&minus; The National Pharmacovigilance Center (NPC)</p><p>-&nbsp; SFDA Call Center: 19999</p><p>-&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states /other countries</strong></p><p><strong>&nbsp;</strong></p><p>-Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms:<br />The maximum dose of Sevikar HCT is 40 mg/10 mg/25 mg once daily. There is no information<br />on overdosage with Sevikar HCT in humans. The most likely effect of Sevikar HCT overdosage<br />is hypotension.<br />The most likely effects of olmesartan medoxomil overdosage are hypotension and tachycardia;<br />bradycardia could be encountered if parasympathetic (vagal) stimulation occurred.<br />Amlodipine overdosage can be expected to lead to excessive peripheral vasodilatation with<br />marked hypotension and possibly a reflex tachycardia. Marked and potentially prolonged<br />systemic hypotension, up to and including shock with fatal outcome, has been reported.</p><p>Non-cardiogenic pulmonary oedema has rarely been reported as a consequence of amlodipine overdose that may manifest with a delayed onset (24-48 hours post-ingestion) and require ventilatory support. Early resuscitative measures (including fluid overload) to maintain perfusion and cardiac output may be precipitating factors.</p><p>Overdosage with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia,<br />hypochloraemia) and dehydration resulting from excessive diuresis.<br />The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia<br />may result in muscle spasm and/or accentuate cardiac arrhythmias associated with the<br />concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products.<br />Treatment:<br />In the event of overdosage with Sevikar HCT, treatment should be symptomatic and supportive.<br />Management depends upon the time since ingestion and the severity of the symptoms.<br />If intake is recent, gastric lavage may be considered. In healthy subjects, the administration of<br />activated charcoal immediately or up to 2 hours after ingestion of amlodipine has been shown to<br />reduce substantially the absorption of amlodipine.<br />Clinically significant hypotension due to an overdose of Sevikar HCT requires active support of<br />the cardiovascular system, including close monitoring of heart and lung function, elevation of the<br />extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be<br />helpful in restoring vascular tone and blood pressure, provided that there is no contraindication<br />to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium<br />channel blockade.<br />Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the<br />patient should be placed in a supine position, with salt and volume replacements given quickly.<br />Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit. The dialysability<br />of olmesartan or hydrochlorothiazide is unknown.<br />The degree to which olmesartan and hydrochlorothiazide are removed by haemodialysis has not<br />been established</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco-therapeutic group: Angiotensin II antagonists, calcium channel blockers and diuretics.<br />ATC code: C09DX03.<br />Sevikar HCT is a combination of an angiotensin II receptor antagonist, olmesartan medoxomil, a<br />calcium channel blocker, amlodipine besilate and a thiazide diuretic, hydrochlorothiazide. The<br />combination of these ingredients has an additive antihypertensive effect, reducing blood pressure<br />to a greater degree than each component alone.<br />Olmesartan medoxomil is an orally active, selective angiotensin II receptor (type AT1)<br />antagonist. Angiotensin II is the primary vasoactive hormone of the renin-angiotensinaldosterone system and plays a significant role in the pathophysiology of hypertension. The<br />effects of angiotensin II include vasoconstriction, stimulation of the synthesis and release of<br />aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the<br />vasoconstrictor and aldosterone-secreting effects of angiotensin II by blocking its binding to the<br />AT1 receptor in tissues including vascular smooth muscle and the adrenal gland. The action of<br />olmesartan is independent of the source or route of synthesis of angiotensin II. The selective<br />antagonism of the angiotensin II (AT1) receptors by olmesartan results in increases in plasma<br />renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone<br />concentrations.<br />In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in<br />arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis<br />during long-term treatment, or of rebound hypertension after abrupt cessation of therapy.<br />Once daily dosing with olmesartan medoxomil provides an effective and smooth reduction in<br />blood pressure over the 24 hour dose interval. Once daily dosing produced similar decreases in<br />blood pressure as twice daily dosing at the same total daily dose.<br />With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after<br />the initiation of therapy, although a substantial proportion of the blood pressure lowering effect<br />is already observed after 2 weeks of treatment.<br />The effect of olmesartan medoxomil on mortality and morbidity is not yet known.<br />The amlodipine component of Sevikar HCT is a calcium channel blocker that inhibits the<br />transmembrane influx of calcium ions through the potential-dependent L-type channels into the<br />heart and smooth muscle. Experimental data indicate that amlodipine binds to both<br />dihydropyridine and non-dihydropyridine binding sites. Amlodipine is relatively vessel-selective,<br />with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. The<br />antihypertensive effect of amlodipine derives from a direct relaxant effect on arterial smooth<br />muscle, which leads to a lowering of peripheral resistance and hence of blood pressure.<br />In hypertensive patients, amlodipine causes a dose-dependent, long-lasting reduction in arterial<br />blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during<br />long-term treatment, or of rebound hypertension after abrupt cessation of therapy.<br />Following administration of therapeutic doses to patients with hypertension, amlodipine<br />produces an effective reduction in blood pressure in the supine, sitting and standing positions.<br />Chronic use of amlodipine is not associated with significant changes in heart rate or plasma<br />catecholamine levels. In hypertensive patients with normal renal function, therapeutic doses of<br />amlodipine reduce renal vascular resistance and increase glomerular filtration rate and effective<br />renal plasma flow, without changing filtration fraction or proteinuria.<br />In haemodynamic studies in patients with heart failure and in clinical studies based on exercise<br />tests in patients with NYHA class II-IV heart failure, amlodipine was found not to cause any<br />clinical deterioration, as measured by exercise tolerance, left ventricular ejection fraction and<br />clinical signs and symptoms.<br />A placebo-controlled study (PRAISE) designed to evaluate patients with NYHA class III-IV<br />heart failure receiving digitalis, diuretics and ACE inhibitors, has shown that amlodipine did not<br />lead to an increase in the risk of mortality and morbidity in patients with heart failure.<br />In a follow-up, long-term, placebo controlled study (PRAISE-2) of amlodipine in patients with<br />NYHA III and IV heart failure without clinical symptoms or objective findings suggestive of<br />underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics,<br />amlodipine had no effect on total or cardiovascular mortality. In this same population amlodipine<br />was associated with increased reports of pulmonary oedema despite no significant difference in<br />the incidence of worsening heart failure as compared to placebo.<br />A randomized double-blind morbidity-mortality study called the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer<br />drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d<br />(ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25<br />mg/d in mild to moderate hypertension.&rdquo;<br />A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a<br />mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous<br />myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other<br />atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left<br />ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current<br />cigarette smoking (21.9%).<br />The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There<br />was no significant difference in the primary endpoint between amlodipine-based therapy and<br />chlorthalidone-based therapy: RR 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints,<br />the incidence of heart failure (component of a composite combined cardiovascular endpoint) was<br />significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs.<br />7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in<br />all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR<br />0.96 95% CI [0.89-1.02] p=0.20.<br />Hydrochlorothiazide is a thiazide diuretic. The mechanism of the antihypertensive effect of<br />thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte<br />reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent<br />amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma<br />renin activity and increases aldosterone secretion, with consequent increases in urinary<br />potassium and bicarbonate loss, and decreases in serum potassium. The renin-aldosterone link is<br />mediated by angiotensin II and therefore coadministration of an angiotensin II receptor<br />antagonist tends to reverse the potassium loss associated with thiazide diuretics. With<br />hydrochlorothiazide, onset of diuresis occurs at about 2 hours and peak effect occurs at about 4<br />hours post-dose, whilst the action persists for approximately 6-12 hours.<br />Epidemiological studies have shown that long-term treatment with hydrochlorothiazide<br />monotherapy reduces the risk of cardiovascular mortality and morbidity.<br />Results of Clinical Studies<br />In a 12-week, double-blind, randomised, parallel-group study in 2492 patients (67% Caucasian<br />patients), treatment with Sevikar HCT 40 mg/10 mg/25 mg resulted in significantly greater<br />reductions in diastolic and systolic blood pressures than treatment with either of the<br />corresponding dual combinations, olmesartan medoxomil 40 mg plus amlodipine 10 mg,<br />olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg and amlodipine 10 mg plus<br />hydrochlorothiazide 25 mg, respectively.<br />The additional blood pressure lowering effect from Sevikar HCT 40 mg/10 mg/25 mg compared<br />to the analogous dual combinations was between -3.8 and -6.7 mmHg for seated diastolic and<br />between -7.1 and -9.6 mmHg for seated systolic blood pressure and occurred within the first 2<br />weeks.<br />The proportions of patients reaching blood pressure goal (&lt; 140/90 mmHg for non-diabetic<br />patients and &lt; 130/80 mmHg for diabetic patients) at week 12 ranged from 34.9% to 46.6% for<br />the dual combination treatment groups compared to 64.3% for Sevikar HCT 40 mg/10 mg/25<br />mg.<br />In a second double-blind, randomised, parallel-group study in 2690 patients (99.9% Caucasian<br />patients), treatment with Sevikar HCT (20 mg/5 mg/12.5 mg, 40 mg/5 mg/12.5 mg, 40 mg/5<br />mg/25 mg, 40 mg/10 mg/12.5 mg, 40 mg/10 mg/25 mg) resulted in significantly greater<br />reductions in diastolic and systolic blood pressure compared to the corresponding dual<br />combinations, olmesartan medoxomil 20 mg plus amlodipine 5 mg, olmesartan medoxomil 40<br />mg plus 5 mg amlodipine and olmesartan medoxomil 40 mg plus 10 mg amlodipine,<br />respectively, after 10 weeks of treatment.<br />The additional blood pressure lowering effect from Sevikar HCT compared to the corresponding<br />dual combinations was between -1.3 and -1.9 mmHg for seated diastolic and between -2.7 and -<br />4.9 mmHg for seated systolic blood pressure.<br />The proportions of patients reaching blood pressure goal (&lt; 140/90 mmHg for non-diabetic<br />patients and &lt; 130/80 mmHg for diabetic patients) at week 10 ranged from 42.7% to 49.6% for<br />the dual combination treatment groups compared to 52.4% to 58.8% for Sevikar HCT.<br />In a randomised, double-blind, add-on study in 808 patients (99.9 % Caucasian patients) not<br />adequately controlled after 8-weeks therapy with olmesartan medoxomil 40 mg plus amlodipine<br />10 mg dual combination treatment with Sevikar HCT resulted in numerically additional seated<br />blood pressure reduction of -1.8/-1.0 mmHg when treated with Sevikar HCT 40 mg/10 mg/12.5<br />mg and a statistically significant additional seated blood pressure reduction of -3.6/-2.8 mmHg<br />when treated with Sevikar HCT 40 mg/10 mg/25 mg compared to the olmesartan medoxomil 40<br />mg plus amlodipine 10 mg dual combination.<br />Treatment with Sevikar HCT 40 mg/10 mg/25 mg triple-combination therapy resulted in a<br />statistically significantly greater percentage of subjects reaching their blood pressure goal<br />compared to olmesartan medoxomil 40 mg plus amlodipine 10 mg dual combination therapy<br />(41.3% vs. 24.2%); while the treatment with Sevikar HCT 40 mg/10 mg/12.5 mg triplecombination therapy resulted in a numerically greater percentage of subjects reaching their blood<br />pressure goal compared to olmesartan medoxomil 40 mg plus amlodipine 10 mg<br />dual-combination therapy (29.5% vs. 24.2%) in subjects not adequately controlled on dualcombination therapy.<br />The antihypertensive effect of Sevikar HCT was similar irrespective of age and gender, and was<br />similar in patients with and without diabetes<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of olmesartan medoxomil, amlodipine and hydrochlorothiazide had<br />no clinically-relevant effects on the pharmacokinetics of either component in healthy subjects.<br />Following oral administration of Sevikar HCT in normal healthy adults, peak plasma<br />concentrations of olmesartan, amlodipine and hydrochlorothiazide are reached in about 1.5 to 3<br />hours, 6 to 8 hours, and 1.5 to 2 hours, respectively. The rate and extent of absorption of<br />olmesartan medoxomil, amlodipine and hydrochlorothiazide from Sevikar HCT are the same as<br />when administered as a dual-fixed combination of olmesartan medoxomil and amlodipine<br />together with a hydrochlorothiazide single-component tablet or when administered as a dualfixed combination of olmesartan medoxomil and hydrochlorothiazide together with an<br />amlodipine single-component tablet with the same dosages. Food does not affect the<br />bioavailability of Sevikar HCT.<br />Olmesartan medoxomil:<br />Absorption and distribution:<br />Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active<br />metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption<br />from the gastrointestinal tract. No intact olmesartan medoxomil or intact side chain medoxomil<br />moiety have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan<br />from a tablet formulation was 25.6%.<br />The mean peak plasma concentration (Cmax) of olmesartan is reached within about 2 hours after<br />oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase<br />approximately linearly with increasing single oral doses up to about 80 mg.<br />Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan<br />medoxomil may be administered with or without food.<br />No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have<br />been observed.<br />Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant<br />protein binding displacement interactions between olmesartan and other highly bound coadministered active substances is low (as confirmed by the lack of a clinically significant<br />interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood<br />cells is negligible. The mean volume of distribution after intravenous dosing is low (16 &ndash; 29 L).<br />Metabolism and elimination:<br />Total plasma clearance of olmesartan was typically 1.3 L/h (CV 19%) and was relatively slow<br />compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of 14C-labelled<br />olmesartan medoxomil, 10 - 16% of the administered radioactivity was excreted in the urine (the<br />vast majority within 24 hours of dose administration) and the remainder of the recovered<br />radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be<br />calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepatobiliary excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other<br />significant metabolite was detected. Enterohepatic recycling of olmesartan is minimal. Since a<br />large proportion of olmesartan is excreted via the biliary route, use in patients with biliary<br />obstruction is contraindicated (see section 4.3).<br />The terminal elimination half life of olmesartan varied between 10 and 15 hours after multiple<br />oral dosing. Steady state was reached after 2-5 days of dosing and no further accumulation was<br />evident after 14 days of repeated dosing. Renal clearance was approximately 0.5 &ndash; 0.7 L/h and<br />was independent of dose.<br />Amlodipine:<br />Absorption and distribution:<br />After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood<br />levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between<br />64 and 80%. The volume of distribution is approximately 21 l/kg. In vitro studies have shown<br />that approximately 97.5% of circulating amlodipine is bound to plasma proteins.<br />The absorption of amlodipine is unaffected by the concomitant intake of food.<br />Metabolism and elimination:<br />The terminal plasma elimination half life is about 35-50 hours and is consistent with once daily<br />dosing.<br />Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the<br />parent compound and 60% of metabolites excreted in the urine.<br />Hydrochlorothiazide:<br />Absorption and distribution:<br />Following oral administration of olmesartan medoxomil and hydrochlorothiazide in combination,<br />the median time to peak concentrations of hydrochlorothiazide was 1.5 to 2 hours after dosing.<br />Hydrochlorothiazide is 68% protein bound in the plasma and its apparent volume of distribution<br />is 0.83 &ndash; 1.14 L/kg.<br />Metabolism and elimination:<br />Hydrochlorothiazide is not metabolised in man and is excreted almost entirely as unchanged<br />active substance in urine. About 60% of the oral dose is eliminated as unchanged active<br />substance within 48 hours. Renal clearance is about 250 &ndash; 300 mL/min. The terminal elimination<br />half-life of hydrochlorothiazide is 10 &ndash; 15 hours.<br />Pharmacokinetics in special populations<br />Paediatric Population:<br />The European Medicines Agency has waived the obligation to submit the results of studies with<br />Sevikar HCT in all subsets of the paediatric population in essential hypertension.<br />Elderly:<br />In hypertensive patients, the olmesartan AUC at steady state was increased by ca 35% in elderly<br />patients (65 &ndash; 75 years old) and by ca 44% in very elderly patients (&ge; 75 years old) compared<br />with the younger age group (see section 4.2).<br />This may be at least in part related to a mean decrease in renal function in this group of patients.<br />The recommended dosage regimen for elderly patients is, however, the same, although caution<br />should be exercised when increasing the dosage.<br />The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger<br />subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and<br />elimination half life in elderly patients. Increases in AUC and elimination half life in patients<br />with congestive heart failure were as expected for the patient age group in this study (see section<br />4.4).<br />Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both<br />healthy and hypertensive elderly patients compared to young healthy volunteers.<br />Renal impairment:<br />In renally impaired patients, the olmesartan AUC at steady state increased by 62%, 82% and<br />179% in patients with mild, moderate and severe renal impairment, respectively, compared to<br />healthy controls (see sections 4.2 and 4.4). The pharmacokinetics of olmesartan medoxomil in<br />patients undergoing haemodialysis has not been studied.<br />Amlodipine is extensively metabolised to inactive metabolites. Ten percent of the substance is<br />excreted unchanged in the urine. Changes in amlodipine plasma concentration are not correlated<br />with the degree of renal impairment. In these patients, amlodipine may be administered at the<br />normal dosage. Amlodipine is not dialysable.<br />The half-life of hydrochlorothiazide is prolonged in patients with impaired renal function.<br />Hepatic impairment:<br />After single oral administration, olmesartan AUC values are 6% and 65% higher in mildly and<br />moderately hepatically impaired patients, respectively, than in their corresponding matched<br />healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in<br />patients with mild hepatic impairment and in patients with moderate hepatic impairment is<br />0.26%, 0.34% and 0.41%, respectively.<br />Following repeated dosing in patients with moderate hepatic impairment, olmesartan mean AUC<br />is again about 65% higher than in matched healthy controls. Olmesartan mean Cmax values are<br />similar in hepatically-impaired and healthy subjects. Olmesartan medoxomil has not been<br />evaluated in patients with severe hepatic impairment (see sections 4.2 and 4.4).<br />Very limited clinical data are available regarding amlodipine administration in patients with<br />hepatic impairment. The clearance of amlodipine is decreased and the half-life is prolonged in<br />patients with impaired hepatic function, resulting in an increase in AUC of about 40% &ndash; 60%<br />(see sections 4.2 and 4.4).<br />Hepatic impairment does not significantly influence the pharmacokinetics of<br />hydrochlorothiazide<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Olmesartan medoxomil/ Amlodipine /Hydrochlorothiazide combination<br />Repeated dose toxicity study in rats demonstrated that the combined administration of<br />olmesartan medoxomil, amlodipine and hydrochlorothiazide neither augmented any of the<br />previously reported and existing toxicities of the individual agents, nor induced any new toxicity,<br />and no toxicologically synergistic effects were observed.<br />No additional mutagenicity, carcinogenicity, and reproductive toxicity studies for Sevikar HCT<br />have been conducted based on the well-understood safety profile of the individual active<br />ingredients.<br />Olmesartan medoxomil<br />In chronic toxicity studies in rats and dogs, olmesartan medoxomil showed similar effects to<br />other AT1 receptor antagonists and ACE inhibitors: raised blood urea (BUN) and creatinine;<br />reduction in heart weight; reduction of red cell parameters (erythrocytes, haemoglobin,<br />haematocrit); histological indications of renal damage (regenerative lesions of the renal<br />epithelium, thickening of the basal membrane, dilatation of the tubules). These adverse effects<br />caused by the pharmacological action of olmesartan medoxomil have also occurred in preclinical<br />trials on other AT1 receptor antagonists and ACE inhibitors and can be reduced by simultaneous<br />oral administration of sodium chloride.<br />Like other AT1 receptor antagonists olmesartan medoxomil was found to increase the incidence<br />of chromosome breaks in cell cultures in vitro, but not in vivo. The overall data of a<br />comprehensive genotoxicity testing programme suggest that olmesartan is very unlikely to exert<br />genotoxic effects under conditions of clinical use.<br />Olmesartan medoxomil was not carcinogenic in rats or transgenic mice.<br />In reproductive studies in rats, olmesartan medoxomil did not affect fertility and there was no<br />evidence of a teratogenic effect. In common with other angiotensin II antagonists, survival of<br />offspring was reduced and pelvic dilatation of the kidney was seen after exposure of the dams in<br />late pregnancy and lactation. In rabbits there was no indication of a fetotoxic effect.<br />Amlodipine<br />Reproductive toxicology<br />Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration<br />of labour and decreased pup survival at dosages approximately 50 times greater than the<br />maximum recommended dosage for humans based on mg/kg.<br />Impairment of fertility<br />There was no effect on the fertility of rats treated with amlodipine (males for 64 days and<br />females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum<br />recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats<br />were treated with amlodipine besilate for 30 days at a dose comparable with the human dose<br />based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as<br />well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.<br />Carcinogenesis, mutagenesis<br />Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to<br />provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of<br />carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum<br />recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated<br />dose for mice but not for rats.<br />Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.<br />*Based on patient weight of 50 kg<br />Hydrochlorothiazide<br />Studies with hydrochlorothiazide have shown equivocal evidence for a genotoxic or carcinogenic<br />effect in some experimental models. However, the extensive human experience with<br />hydrochlorothiazide has failed to show an association between its use and an increase in<br />neoplasma<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core<br />&bull; Starch, pregelatinised maize<br />&bull; Silicified microcrystalline cellulose (microcrystalline cellulose and silica colloidal anhydrous)<br />&bull; Croscarmellose sodium<br />&bull; Magnesium stearate<br />Film coat<br />&bull; Opadry&reg; II Pink 85F24118 for Sevikar HCT 20 mg/5mg /12.5mg tablet<br />&bull; Opadry&reg; II Yellow 85F32331 for Sevikar HCT 40mg/5mg/12.5mg &amp; 40mg/5mg/25mg tablet<br />&bull; Opadry&reg; II Pink 85F25437 for Sevikar HCT 40mg/10mg/12.5mg &amp; 40mg/10mg/25mg tablet<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.<br />Store below 30 &deg;C<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum/Aluminum Blister Packs of 28 film-coated tablets<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited
Jeddah – Saudi Arabia
Under license from
Daiichi Sankyo Co. Ltd.
Tokyo-Japan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August.2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>